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The Role of A2BR Signaling in Adenosine Dependent Lung Disease 
Publication No. _________________ 
Yang Zhou, B.S. 
Supervisory Professor: Michael R. Blackburn, Ph.D. 
 
Chronic lung diseases and acute lung injuries are two distinctive 
pulmonary disorders that result in significant morbidity and mortality. Adenosine 
is a signaling nucleoside generated in response to injury and can serve both 
protective and destructive functions in tissues and cells through interaction with 
four G-protein coupled adenosine receptors: A1R, A2AR, A2BR, and A3R. 
However, the relationship between these factors is poorly understood. Recent 
findings suggest the A2BR has been implicated in the regulation of both chronic 
lung disease and acute lung injury. The work presented in this dissertation 
utilized the adenosine deaminase-deficient mouse model and the bleomycin-
induced pulmonary injury model to determine the distinctive roles of the A2BR at 
different stages of the disease. Results demonstrate that the A2BR plays a 
protective role in attenuating vascular leakage in acute lung injuries and a 
detrimental role at chronic stages of the disease. In addition, tissues from 
patients with chronic obstructive pulmonary disease and idiopathic pulmonary 
fibrosis were utilized to examine adenosine metabolism and signaling in chronic 
lung diseases. Results demonstrate that components of adenosine metabolism 
and signaling are altered in a manner that promotes adenosine production and 
signaling in the lungs of these patients. Furthermore, this study provides the first 
evidence that A2BR signaling can promote the production of inflammatory and 
fibrotic mediators in patients with these disorders. Taken together, these findings 
suggest that the A2BR may have a bi-phasic effect at different stages of lung 
disease. It is protective in acute injury, whereas pro-inflammatory and pro-fibrotic 
at the chronic stage. Patients with acute lung injury or chronic lung disease may 
both benefit from adenosine and A2BR-based therapeutics. 
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CHAPTER 1 
INTRODUCTION 
Chronic lung diseases are featured by processes such as inflammation 
and tissue remodeling that contribute to a progressive pulmonary function 
decline. The prominent and deadly features in these disorders make them the 
third leading cause of death in the US following cancer and cardiovascular 
disease. Acute lung injury and acute respiratory distress syndrome contribute 
significantly to critical illness. Although chronic lung diseases and acute lung 
injuries exhibit distinct molecular basis and pathogenesis, they both result in 
significant morbidity and mortality and some overlapping features are observed in 
these disorders. Studies are needed to investigate the mechanisms involved in 
disease progression and the similarities and differences between these 
disorders.   
  
Chronic Lung Disease and Acute Lung Injury 
Chronic lung disease describes pulmonary disorders where persistent 
inflammation and structural alternation contribute to progressive loss of lung 
function (1). Examples of chronic lung disease include asthma, chronic 
obstructive pulmonary disease (COPD) and interstitial lung disease. Asthma is 
characterized by episodic airway obstruction, airway hyperresponsiveness, 
cellular infiltration, mucus hypersecretion and airway remodeling (2, 3). COPD is 
accompanied by chronic bronchitis and emphysema (4), while interstitial lung 
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diseases exhibit varying degrees of airway fibrosis and inflammation (5, 6). 
These lung diseases afflict numerous individuals and result in hundreds of 
thousands of dollars in annual health costs. Currently there are no effective 
treatments, especially during the chronic phase of these diseases. The 
inflammatory response seen in these disorders involves the recruitment of 
multiple types of inflammatory cells and results in the release of a number of 
soluble mediators that drive inflammation and remodeling processes in the lung 
(7, 8). Although the mechanisms responsible for the genesis of inflammation and 
the regulation of tissue remodeling have been well established, relatively little is 
described about the signaling pathways that serve to regulate the progressive 
and chronic nature of these diseases (9).  
A normal wound healing response is involved in chronic lung diseases. 
For example, collagen deposition, epithelial cell remodeling and angiogenesis 
around the bronchial airways are characteristic features in asthma. Interstitial 
lung diseases are featured by fibroblast proliferation and extensive extracellular 
matrix deposition, whereas imbalances in matrix proteases and anti-proteases 
and destruction of the alveolar airways are often observed in patients with 
COPD. It has been suggested that the excessive tissue remodeling processes 
that are observed in chronic lung diseases result from overactive or deregulated 
wound healing pathways (2, 10). Efforts targeted at understanding the molecular 
pathogenesis of these diseases and how the diseases progress will lead to better 
treatment options and decreased mortality. 
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Acute lung injury and acute respiratory distress syndrome can develop in 
a number of different clinical conditions such as pneumonia, acid aspiration, 
major trauma, or prolonged mechanical ventilation (11). Experimental and clinical 
studies have demonstrated that the pathogenesis of TH1 inflammation and acute 
lung injury are characterized by pulmonary trafficking of polymorphonuclear 
leukocytes (PMNs) into the lungs (12). Activation of circulating PMNs initiates the 
recruitment of leukocytes to the lung (13). Transendothelial migration and 
transepithelial migration into the lung interstitium and into the alveolar space are 
initiated following PMNs adherence to the pulmonary vessel wall. Enhanced 
inflammation and damage is associated with enhanced permeability of 
microvasculature, thus pulmonary vascular barrier function serves as a protective 
barrier in acute stages of injury (14, 15). However, the molecular mechanisms 
underlying PMN trafficking in the lung is not fully understood. Better 
understanding the substantial mechanisms of PMN migration into the tissue in 
ALI and ARDS-typical symptoms, including the regulation of microvascular 
permeability, expression of adhesion molecules, release of cytokines and 
chemokines, will help prevent or treat these acute injuries (16, 17).  
 
Adenosine Metabolism and Signaling 
Adenosine is a signaling molecule that is generated at sites of organ 
damage and tissue injury and is therefore increased during tissue hypoxia and 
inflammation (18). ATP is released into the extracellular space, where it is quickly  
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Figure 1  
Adenosine metabolism and signaling. In response to cellular stress and 
damage, ATP is released into the extracellular space and is rapidly 
dephosphorylated by extracelluar nucleotidases.  CD73 catalyzes the formation 
of extracellular adenosine from AMP.  Extracellular adenosine can interact with 
seven-transmembrane adenosine receptors, A1R, A2AR, A2BR, and A3R, which 
are coupled by heterotrimeric G proteins to various second messenger 
systems, or it can be transported into cells via facilitated nucleoside 
transporters, such as ENT1.  Both extracellular and intracellular adenosine can 
be deaminated to inosine by adenosine deaminase (ADA).  Intracellular 
adenosine can be secreted or phosphorylated back to ATP.  The first step in 
this process is catalyzed by adenosine kinase (AK). 
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dephosphorylated by extracellular nucleotidases to form extracellular adenosine 
(19). Adenosine can enter cells via facilitated nucleoside transporters, or function 
on cells by interacting with G protein coupled adenosine receptors (20). Both 
extracellular adenosine and intracellular adenosine can be deaminated to inosine 
by the enzyme adenosine deaminase (ADA) (21) (Figure 1). Adenosine has 
potent anti-inflammatory as well as pro-inflammatory functions (22). Expression 
profiles of specific adenosine receptors on specific organs and cells likely 
mediate the distinct pro- and anti-inflammatory roles of adenosine (18). Four 
adenosine receptors have been identified: A1R, A2AR, A2BR and A3R. These 
receptors have a seven membrane-spanning structure and are coupled to 
heterotrimeric G proteins. Each adenosine receptor has a unique affinity and a 
distinct cellular and tissue distribution (20, 23). Adenosine receptor signaling can 
influence cellular physiology through a variety of mechanisms and access 
multiple intracellular signaling pathways (24). A1R and A3R are coupled to 
inhibitory G proteins and can downregulate adenyl cyclase activity to decrease 
cAMP levels, while A2AR and A2BR are coupled to stimulatory G proteins and 
increase cAMP levels. In addition, adenosine receptors are coupled to other 
signaling molecules such as Phospholipase C, PI3K and MAPKs. 
Adenosine plays distinctive roles in chronic versus acute lung injuries. In 
chronic lung diseases, elevations in adenosine are found in these patients (25) 
and inhaled adenosine and/or its precursor AMP elicit bronchoconstriciton in 
asthmatics and COPD patients (26). Adenosine is generated following injury and 
it can promote processes that are critical in wound healing such as angiogenesis, 
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matrix production and the regulation of inflammation. An A2AR agonist can 
increase the rate of wound healing by increasing the production of extracellular 
matrix and angiogenesis (27). A2AR and A2BR activation promotes fibroblast 
differentiation and matrix production (28-30). It also results in VEGF production 
(31), endothelial cell proliferation (32), and granulation tissue formation, thus 
leading to angiogenesis (33). In addition, the engagement of adenosine receptors 
influences mast cell degranulation (34), eosinophil function (35) and stimulates 
mucus production by airway epithelium (36). These findings suggest that 
adenosine signaling can influence cellular events in chronic lung diseases and 
adenosine is suggested to play an important role in regulating the chronic nature 
of asthma and COPD. Whereas it appears that adenosine plays a largely 
detrimental and tissue-destructive role in the regulation of chronic lung disease, 
substantial evidence suggests that extracellular adenosine signaling plays 
important anti-inflammatory roles in acute lung injury through engaging its 
receptors. During acute injuries, adenosine is generated in extracellular space to 
regulate the acute inflammatory response. CD39 and CD73 are the enzymes that 
coordinate a two-step conversion of adenosine from its precursors. It has been 
shown that CD39 and CD73 levels are elevated in the lungs following LPS 
stimulation and neutrophil accumulation was enhanced in mice treated with 
inhibitors of these enzymes and in CD39 and CD73-deficient mice (17, 37). In 
addition, numerous genetic and pharmacologic antagonism studies have 
identified specific adenosine receptors involved in tissue protection in various 
acute injury models such as LPS induced injury (38), ventilator-induced lung 
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injury (39), hypoxia-induced injury (14), and ischemia reperfusion injury (40-44). 
Because of the diverse effects of adenosine and its receptors, extensive 
research has been dedicated to developing potential therapeutics targeting 
adenosine metabolism and signaling. 
 
Adenosine Deaminase-deficient Mouse Model 
A mouse model of adenosine-mediated pulmonary injury has been 
developed in our lab and it has allowed us to examine the consequences of 
adenosine elevations on pulmonary inflammation and tissue remodeling. The 
purine catabolic enzyme, ADA, decreases the levels of adenosine as well as 
deoxyadenosine in tissues and cells. Genetic removal of ADA results in a 
significant elevation of concentrations of these substrates systemically. A severe 
combined immunodeficiency is observed in ADA-deficient mice because of the 
accumulation of deoxyadenosine in the thymus and spleen (45, 46), while 
adenosine accumulations result in the development of pulmonary inflammation 
and lung architecture remodeling, features consistent with various aspects of 
chronic lung disease seen in human. ADA-deficient mice spontaneously develop 
signs of respiratory distress and progressive pulmonary injury characterized by 
increases in activated alveolar macrophages, enlargement of alveolar space, 
mucus production in bronchial airways, and airway hyperresponsiveness. They 
also develop subepithelial fibrosis and extracellular matrix deposition, features 
consistent with interstitial lung diseases (47, 48). In addition, there is an up-
regulation in levels of cytokines and pro-inflammatory mediators commonly 
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elevated in association with asthma and COPD including serum IgE and TH2 
cytokines (47, 49), mediators of airspace enlargement such as matrix 
metalloproteases and cathepsins (49). These features are seen in patients with 
chronic lung diseases and are related to increases in lung adenosine levels. 
Additional evidence suggesting that the phenotypes seen in ADA-deficient 
mice are directly mediated by adenosine levels is seen through the use of 
exogenous ADA enzyme therapy. ADA covalently linked to polyethylene glycol 
(Peg-ADA) was used to treat ADA-deficient mice and prevented or reversed 
many aspects of the pulmonary phenotype  (45, 50). If ADA-deficient mice are 
kept on PEG-ADA enzyme therapy from birth, the phenotype is completely 
prevented allowing normal development and life span. In addition, ADA enzyme 
therapy can be used to treat ADA-deficient mice even after they have established 
severe pulmonary phenotypes, thus reversing pulmonary injury. These findings 
display a clear correlation between adenosine levels, its contribution to the 
overall morbidity in this model, and the presence of lung pathology. The ADA-
deficient mouse model and the use of ADA enzyme therapy provide us a great 
system to characterize the role of adenosine in the pathology of chronic lung 
diseases.  
 
A2B Adenosine Receptor 
            The A2BR is widely expressed in tissues and cells and has the lowest 
affinity for adenosine (20). It has been shown that all cell types in the lung 
express A2BR transcripts and the levels of expression increase in inflammatory 
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environments. It is generally accepted that A2BR is coupled to Gs proteins to 
activate adenyl cyclase and increase cAMP levels (51, 52). In addition, regulatory 
proteins of the Gq family are thought to play a role in the coupling of A2BRs to 
phospholipase C (PLC) in human mast HMC-1 cells (53). A2BR activation has 
both anti-inflammatory and pro-inflammatory actions and both pro- and anti-
fibrotic roles (54). Numerous studies have shown that the A2BR has tissue 
destructive functions in that the engagement of the A2BR can promote the 
differentiation of pulmonary fibroblasts into myofibroblasts and hence increase 
the deposition of collagen and fibrosis (30). Engagement of the A2BR can 
mediate the direct expression of pro-inflammatory cytokines such as IL-8, IL-4 
and IL-13 from human HMC-1 cells (53, 55) and mouse mast cells (56). 
Consistent with this, treatment of ADA-deficient mice with an A2BR antagonist 
resulted in diminished pulmonary inflammation and fibrosis (57). In contrast to 
these results, recent observations usinig A2BR knockout mice suggest that the 
ablation of the A2BR causes low-grade inflammation and enhanced leukocyte 
adhesion to the vasculature (58). In addition, the deletion of this Gs-coupled 
receptor on mouse bone marrow-derived mast cells leads to decreased levels of 
cAMP and enhances mast cell activation (59). Moreover, it is proposed that A2BR 
signaling is responsible for the phosphorylation of vasodilator-stimulated 
phosphoprotein, which controls the geometry of actin-filaments and mediates 
junctional protein distribution, thereby promoting increases in endothelial barrier 
functions by affecting the characteristics of the endothelial junctional complex (3). 
Clearly, discrepancies exist when investigating the roles of the A2BR. These 
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findings suggest that engagement of the A2BR is complex and additional studies 
are needed in order to clarify the A2BR’s multiple inflammatory and remodeling 
roles during the course of injury and repair.  
 
Dissertation Overview 
The overall aim of this dissertation is to better understand the role of the 
A2B adenosine receptor in pulmonary disease. To accomplish this goal, I have 
utilized two animal models to characterize A2BR’s role from different aspects and 
at different stages of lung disease. In Chapter 3, I characterized the phenotypes 
in ADA/A2BR double knockout mice to study the contribution of this receptor in 
adenosine dependent lung injury. Based on a previous receptor antagonism 
study shown that the A2BR plays a tissue-destructive and pro-fibrotic role, I 
hypothesized that the genetic removal of the A2BR from ADA-deficient mice 
would lead to enhanced pulmonary injury and damage. Unexpectedly, lack of the 
A2BR in ADA-deficient mice resulted in loss of vascular barrier functions and 
ADA/A2BR double knockout mice showed enhanced pulmonary phenotypes 
compared to ADA-deficient mice (60). I then hypothesized that the A2BR may play 
a homeostatic and protective role in regulating vascular barrier function during 
the early or acute stage of pulmonary injury, while a tissue-destructive and pro-
fibrotic role at the chronic stage of the disease. In Chapter 4, I utilized an animal 
model of pulmonary fibrosis to directly investigate the bi-phase role of A2BR at 
different stages of lung injury. Finally, in Chapter 5, I utilized specimens from 
patients with chronic lung disease to further investigate the roles of the A2BR in 
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human disease. I hypothesized that adenosine metabolism and signaling are 
altered in human diseases. My findings suggest that A2BR signaling pathways are 
enhanced in severe diseases and that these pathways play important roles in 
exacerbating disease status.  
The findings in this dissertation raise the possibility that adenosine-based 
therapeutics may be beneficial in the treatment of chronic lung diseases. They 
also suggest that A2BR signaling has important anti-inflammatory activities during 
early stages of lung disease that were revealed by the global genetic removal of 
the A2BR, whereas A2BR engagement during active disease may contribute to 
disease progression. As the A2BR antagonist is under phase II clinical trials to 
treat chronic lung disease, these findings are particularly timely and important. 
Our findings suggest that the stage of disease and the degree of A2BR 
antagonism or agonism will be critical variables to assess when using A2BR 
based therapeutics in the treatment of lung diseases. Overall, these studies 
provide novel insight into the role of the A2BR in pulmonary disease and will aid in 
the development of novel therapies. 
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CHAPTER 2 
EXPERIMENTAL PROCEDURES 
 
Generation and Genotyping of Mouse Lines 
ADA-deficient mice were generated and genotyped as previously 
described (46). Mice homozygous for the null Ada allele were designated ADA-
deficient (ADA-/-). Mice heterozygous for the null Ada allele were designated as 
control mice (ADA+). ADA/A2BR double knockout mice were generated by mating 
ADA-/- mice with A2BR-deficient mice (A2BR-/-). Mice were congenic on C57BL/6 
background, and phenotypic comparisons were conducted among littermates. 
Animal care was in accordance with NIH guidelines and the Animal Care 
Committee at the University of Texas Health Science Center at Houston. All 
animals were housed under strict containment protocols and maintained in 
ventilated cages equipped with microisolator lids. Serologies on cage littermates 
were negative for 12 of the most commonly seen viruses in mice. No evidence of 
fungal, parasitic, or bacterial infection was found. 
 
ADA Enzyme Therapy 
Polyethylene glycol modified-ADA (PEG-ADA) was generated by the 
covalently linking purified bovine ADA with activated polyethylene glycol (45). 
ADA-/- mice were injected intramuscularly with Peg-ADA on postnatal days 1, 5, 
9, 13, 17(0.625, 1.25, 2.5, 2.5 and 2.5 units, respectively) and intraperitoneal 
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injections on postnatal day 21 (5 units). Animals were sacrificed on postnatal day 
35 (14 days after the last Peg-ADA injection). 
Bronchial Alveolar Lavage and Histology 
Avertin was used to anesthetize the animals, and airways were lavaged 4 
times with 0.3 ml PBS; about 1 ml of pooled lavage fluid was able to be 
recovered. Total cell numbers were determined by counting on a hemocytometer. 
Cellular differentials were determined by cytospining BAL aliquots onto 
microscope slides and staining with Diff-Quick (Dade Behring) for. After lavage, 
the lungs were inflated with 10% buffered formalin phosphate in PBS at 25 cm of 
pressure and then fixed at 4°C overnight. Formalin-fixed lungs were dehydrated 
in ethanol gradients, and then paraffin embedding was performed. 5 μm tissue 
sections were cut and collected on microscope slides and stained with H&E 
(Shandon-Lipshaw) according to manufacturer’s instructions. 
Immunostaining on Mouse Lung Sections 
Rehydrated slides were quenched with hydrogen peroxide (3%), followed  
by antigen retrieval for 30 min at 95°C (Dako Corp.), and endogenous avidin and 
biotin blocking was performed with a Biotin Blocking System (DAKO Corp.). 
Slides were incubated with Rat Anti-mouse Neutrophils Antibody (AbD SeroTec, 
1:500 dilution, overnight at 4°C). ABC Streptavidin reagents and individual 
appropriate secondary antibodies were used to incubate lung sections, and then 
lung sections were developed with 3, 3'-diaminobenzidine (Sigma-Aldrich) and 
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methyl green counterstaining was performed. Slides were coversliped with 
Vectashield (Vector Laboratories) mounting medium.  
Airspace Size Measurement 
Mean chord lengths on H&E-stained lung sections cut from a constant-
pressure infused lungs were used to determine the average alveolar airspace 
size (47). Representative images were captured, and overlaid with a grid 
consisting of 53 black lines at 10.5-μm intervals. This line grid was subtracted 
from the lung images using Image-Pro Plus image analysis software (Media 
Cybernetics), and the mean chord length of the alveolar airspaces were 
determined by measuring and averaging the resultant lines. 10 non-overlapping 
images of each lung were used to determine the final average mean chord 
lengths.  
TUNEL Analysis  
ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon) was 
used and end labeling of exposed 3′-OH ends of DNA fragments in paraffin-
embedded tissue was undertaken under the instructions provided by the 
manufacturer. After staining, in each section a minimum of 300 positive-labeled 
cells were evaluated visually. The amount of positive-labeled cells was 
expressed as a percentage of total nuclei evaluated.  
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RT-PCR and Quantitative RT-PCR 
Whole lung RNA was extracted from frozen lungs using Trizol reagent 
(Invitrogen Corp.). RNA samples were digested with RNase-free DNase-1 
(Invitrogen Corp.). A Superscript One-Step RT-PCR (Invitrogen Corp.) reaction 
with β-actin or A2BR specific primers were performed using lung RNA (1μg)  
following the manufacturer’s instruction. Real-time quantitative RT-PCR was 
performed to quantitate transcript levels. Smart Cycler (Cepheid) was used to 
determine A2BR and β-actin transcripts using Taqman probes. Cytokine and 
chemokine transcripts were analyzed using SYBR Green method or Taqman 
probes on the Smart Cycler RT-PCR machine (Cepheid). Primer sequences 
were the same as previously used for the transcripts examined (47, 48, 57, 61, 
62). Specific gene transcript levels were calculated either by generating a 
standard curve from template dilutions and the PCR amplification, or 18S 
ribosomal RNA was used an a normalizer and the comparative Ct method (2∆∆Ct) 
was used to present the data as mean normalized transcript levels (63).  
 
Western Blot Analysis 
Frozen lungs samples were homogenized and lysed on ice with protein 
lysis buffer (1M Tris pH7.4, 1M NaCl, 1% Triton-X 100) containing 1× protease 
inhibitor cocktail (Roche Diagnostics). After vortexing the lysates vigorously, 
lysates were cleared by centrifugation at 14,000rpm for 15 min at 4°C. 
Electrophoresis was performed using 50 micrograms/sample of total protein on 
10% SDS-PAGE gels and transferred overnight at 4°C to Immobilon-P PVDF 
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membranes (Millipore), and Western blotting analysis was performed as 
previously described (64). The following antibodies were used: rat monoclonal 
anti-E-selectin antibody (R&D Systems; 1:5,000 dilutions), rabbit polyclonal anti-
ICAM-1 antibody (Santa Cruz Biotechnology.; 1:200 dilution), rabbit monoclonal 
anti-IκB-α antibody (abcam; 1:5,000 dilution), mouse monoclonal anti-β-actin 
antibody (Sigma-Aldrich; 1:5,000 dilution). Secondary antibodies are: anti-rabbit 
IgG-HRP (eBioscience; 1:10,000 dilution), anti-mouse IgG-HRP (eBioscience; 
1:10,000 dilution), and anti-rat IgG-HRP (Sigma-Aldrich; 1:10,000 dilution). 
Chemiluminesce signal were detected (Pierce). 
 
Cytokine and Chemokine Analysis 
The levels of the cytokines IL-1α, IL-1β and the chemokines CXCL-1, 
MCP-1, LIF, RANTES and MIG were examined. Blood was collected using EDTA 
as an anticoagulant. The blood was centrifuged at 1,200rpm for 20 min to obtain 
plasma. BAL fluid was collected as described previously and was centrifuged to 
remove cells. Plasma and the BAL fluid supernatants were then used to 
quantitate the amount of these cytokines and chemokines by using the Milliplex 
mouse cytokine/chemokine panel (Millipore) per the manufacturer’s instructions.  
 
Measurement of Vascular Permeability 
BAL fluid was collected as previously described and was centrifuged to 
remove cells. BAL fluid supernatants were then used to determine total protein 
content by Bradford Assay (BioRad). To assess pulmonary edema, lungs (n = 6) 
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were weighed and dried. Weight ratios before and after drying were used to 
determine lung water content. Organ vascular permeability was quantified by 
intraperitoneal administration of Evans blue dye (0.2 mL of 0.5% in PBS). 
Circulation was perfused with PBS and the heart and lung were harvested four 
hours after the dye injection. After formamide extraction (55°C Overnight), organ 
Evans blue concentrations were quantified by measuring absorbances at 610 nm 
with subtraction of reference absorbance at 450 nm. The contents of Evans blue 
dye were determined by generating a standard curve from dye dilutions.  
Mucus index  
Periodic acid-Schiff (PAS)-staining was performed and the amount of 
produced mucus in bronchial airways was calculated by determining the amount 
of PAS positively labeled material using Image-Pro Plus analysis software (Media 
Cybernetics). PAS-positive areas were identified and separated on digitized 
images, and the averaged intensities of pixel of each color channel (red, blue, 
and green) were calculated. After repeating the same procedure for each image, 
the average values were used to calculate the area (M) and intensity (I) of PAS-
stained material in major and bronchial airways. In addition, the area (A) of the 
total epithelium (including both PAS-negative and positive areas) was 
quantitated. The equation (M x I)/A was used to determine the mucus index. 
Averages of 10 pictures from each lung including both small and large bronchial 
airways were used to determine the final indices. All quantitative studies were 
performed blinded.  
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Whole Mount Immunohistochemistry for CD31 on Tracheas 
Whole mount immunohistochemistry on tracheas were performed as 
described previously (65). Tracheas were cut and removed from mice and then 
washed with cold PBS. Insect pins onto silicone polymers were used to flatten 
tracheas after removing surrounding tissues. PBS was used to wash tracheas for 
10 min and the zinc fixative (BD Pharmingen) was used to fix tracheas at least 
overnight. 3 PBS washes for 5 min per wash were performed after fixation. PBS 
containing 1% Triton X-100 was then used to permeabilize tracheas for 300 min 
were. 0.6% hydrogen peroxide was used to block endogenous peroxidase 
activity by incubating tissues for 30 min. Then Immunohistochemistry for CD31 
was conducted with an anti-rat Ig horseradish peroxidase detection kit (BD 
Pharmingen) according to the manufacturer's instructions. Tissues were 
incubated overnight with a 1:250 dilution of rat anti-mouse CD31 antibody (BD 
Pharmingen). Permount (Fisher) was then used to mount the tissues after 
dehydration. 
Quantification of BAL Fluid Adenosine Levels 
Mice were anesthetized with avertin, and lungs were lavaged 4 times with 
0.3 ml PBS containing 2μM dipyridamole and 5μM DCF; 0.95-1 ml of pooled 
lavage fluid was recovered. Adenosine was separated and quantified using 
reverse-phase HPLC. 
 
18 
 
Intratracheal Bleomycin Treatment 
Avertin (250 mg/kg, intraperitoneally) was used to anesthetize 10-week 
old female wild type or A2BR-/- mice, and saline alone or 2.5 U/kg bleomycin 
(Teva Parenteral Medicines, Inc. Irvine, CA) diluted in 50 µl sterile saline was 
instilled intratracheally. Endpoints were examined at 7 and 21 days after 
challenge. 
 
Intraperitoneal Bleomycin Treatment  
6-week old male WT or A2BR-/- mice were treated with 0.035 U/g 
bleomycin (Teva Parenteral Medicines, Inc. Irvine, CA) diluted in 150 µl sterile 
PBS or PBS alone intraperitoneally. Mice were treated twice weekly for 4 weeks 
and were weighed and sacrificed on day 33. Endpoint at day 10 was also 
examined after 3 injections. 
 
Fibrosis Assessment 
The Sircol assay (Biocolor Ltd., Carrick, UK) was used to quantitate 
soluable collagen levels in BAL fluid. Ashcroft scores were determined on H&E-
stained lung sections. Twenty fields per section were used to determine the 
Ashcroft score blinded. 4 mice per group for controls and 6 mice per group for 
Bleomycin-treated mice were examined. 
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Human Subjects 
Deidentified human open lung biopsy tissue samples were obtained from 
the Lung Tissue Research Consortium (LTRC) (Table 2.1). Patients were 
classified as Stage 0 COPD, Stage 4 COPD, Mild IPF and Severe IPF according 
to spirometry, pathological specimen and high resolution CT scan. Stage 0 
COPD and Mild IPF patients with preserved lung functions were used as controls 
in comparison to Stage 4 COPD and Severe IPF patients. For ex vivo culture 
experiments, macrophages were isolated from lavage fluid collected from Stage 
4 COPD or Severe IPF patients that were lavaged as part of routine diagnostic 
procedures. 
 
Quantitative RT-PCR for Human Samples 
Tissue RNA was isolated from frozen lung tissue using Trizol reagent 
(Invitrogen Corp.). RNA was purified through an RNA-purification column 
(Qiagen) and treated using RNase-free DNase (Invitrogen Corp.). Transcript 
levels were quantified using Taqman real-time quantitative RT-PCR. Primer 
sequences for the transcripts examined are found in Table 2.2. Specific transcript 
levels were determined through comparison to a standard curve generated from 
the PCR amplification of template dilutions, and normalized to 18S ribosomal 
RNA and presented as mean transcript levels %18s RNA. 
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Table 2.1 Study Population 
 
Parameter Stage 0 COPD1 Mild IPF2 Stage 4 COPD3 Severe IPF4 
 
N                                4                     10                          10                    10 
Age, yrs               69 (61-78)       60 (50-77)              50 (44-63)       54 (26-62) 
Sex, M/F                  1/3                    6/4                         6/4                   7/3 
Pack-yrs smoking 25 (25-50)a      8 (3-10)b              36 (1-120)c        20 (3-32)d 
Smoking status 
Ever/Never               4/0                   5/4e                        10/0                  4/5e      
FEV1, % pred     86 (84-89)      92 (66-109)             20 (12-40)*       38 (30-46)# 
FVC, % pred     107 (80-113)    89 (80-105)             54 (13-77)*       38 (25-43)# 
FEV1/FVC, %     60 (50-80)       80 (60-90)               30 (20-60)*       90 (70-100) 
 
 
Data are presented as median (interquartile range). M/F: male/female; FEV1: 
forced expiratory volume in one second; % pred: % predicted; FVC: forced vital 
capacity. 1: Stage 0 COPD is defined as FEV1, % pred > 80; 2: Mild IPF is 
defined as FVC, % pred > 80; 3: Stage 4 COPD is defined as FEV1, % pred < 50; 
4: Severe IPF is defined as FVC, % pred < 50; a: data available for 3/4 Stage 0 
COPD patients; b: data available for 5/10 Mild IPF patients; c: data available for 
9/10 Stage 4 COPD patients; d: data available for 4/10 Severe IPF patients; e: 
data available for 9/10 Mild or Severe IPF patients. *: p<0.05 compared with 
Stage 0 COPD patients; #: p<0.05 compared with Mild IPF patients.     
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Table 2.2 Primer pairs and internal probe sequences 
 
Gene Accession Number Sequences 
CD73 NM_002526 
1447+GACAGAGTAGTCAAATTAGATG 
1511-TGAGAGGGTCATAACTGG 
1471+FAM TCTTTGCACCAAGTGTCGAGTGC 
ADA NM_000022 
264+CTGCTGAACGTCATTGG 
340-GCAGGCATGTAGTAGTC 
281+FAM CATGGACAAGCCGCTCACCC 
AK NM_006721 
1092+CCACTATGCAGCAAGCATC 
1156-GGAAGTCTGGCTTCTCAGG 
112+FAM 
TAATTAGACGGACTGGCTGCACCTT 
ENT1 NM_001078177 
1413+CCAGCCGTGACTGTTGAG 
1489-CAGGACACAGGAATGAAGTAAC 
1438+FAM CCAGCATCGCAGGCAGCAGC 
A1R NM_000647 
1147+GCTGGCTGCCTTTGCAC 
1215-GGATGCTGGGCTTGTGG 
1165+FAM 
TCCTCAACTGCATCACCCTCTTCTGC 
A2AR NM_000675 
838+ATGCTGGGTGTCTATTTGCG 
902-TGGCTCTCCATCTGCTTCAG 
865+FAM CTGGCGGCGCGACGACA 
A2BR NM_000676 
977+CACTGAGCTGATGGACCACTC 
1040-CAGTGACTTGGCTGCATGG 
1018-FAM TCCCGCTGGAGGGTGGTCCT 
A3R NM_000677 
708+CCCTACAGACGGATCTTGCTG 
777-TGTTGGGCATCTTGCCTTC 
734+FAM CCTGTCCCTGTGGAGGTTCCCCT 
IL-6 NM_000600 
153+ CCCCCAGGAGAAGATTCCA 
223- TCAATTCGTTCTGAAGAGGTGAG 
173+FAM 223- 
TCAATTCGTTCTGAAGAGGTGA 
IL-8 NM_000584 
100+TCTTGGCAGCCTTCCTGA 
182-GCACTGACATCTAAGTTCTTTAGCACT 
121+FAM CTGCAGCTCTGTGTGAAGGT 
OPN NM_000582 
619+GGACTGAGGTCAAAATCTAAGAAG 
693-GGTGATGTCCTCGTCTGTAG 
646+FAM CGCAGACCTGACATCCAGTACCCT 
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Enzyme Activity Assay 
Lungs were homogenized and lysed on ice with protein lysis buffer (50mM 
Tris pH7.4, 150mM NaCl, 1% Triton-X 100, 0.1%SDS, 0.5% Na Deoxycholate) 
freshly supplemented with 1× protease inhibitor cocktail (Roche Diagnostics). 
Lysates were vigorously vortexed and cleared by centrifugation at 14,000rpm for 
15 min at 4°C. To quantify CD73 enzyme activity, 5 µg protein extracts were 
incubated with with 100 µM AMP at 37°C for 30 min in the presence of 1 µM 
deoxyconformycin in HEPES buffer, with or without 100 µM CD73 inhibitor 
adenosine- 5'- O- (α, β- methylenediphosphate) (AOPCP). To quantify ADA 
enzyme activity, 10 µg protein extracts were incubated with with 0.2 mM 
adenosine at 37°C for 60 min in HEPES buffer with or without 1 µM 
deoxyconformycin. Heat-inactive protein extracts were used as negative controls. 
Reactions were terminated at 95 degree for 5 min. Reaction mixtures were then 
analyzed by reversed-phase (C18) HPLC which permitted direct separation, 
identification, and quantitation of enzymatic products (45). Enzyme specific 
activity is given as nmol product formed per min per mg protein (nmol/min/mg 
protein). 
 
Histology and Immunostaining of Human Lung Sections 
HOPE or paraformaldyhyde fixed lung samples were dehydrated, and 
embedded in paraffin, and 5 μm sections were cut and collected on microscope 
slides and H&E staining was performed (Shandon-Lipshaw) according to 
manufacturer’s instructions. For CD73 immunostaining, HOPE-fixed sections 
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were deparaffinized in isopropanol at 60°C and rehydrated in 70% acetone. 
Rehydrated slides were quenched with 1% hydrogen peroxide and endogenous 
avidin and biotin blocking was performed using a Biotin Blocking System (DAKO 
Corp.). Slides were incubated with Mouse Anti-human CD73 Antibody (Hycult 
Biotechnology, 1:50 dilution, overnight at 4°C). For A2BR immunostaining, 
rehydrated slides were quenched with 1% hydrogen peroxide, antigen retrieval 
performed (Dako Corp.), and endogenous avidin and biotin blocking was 
performed using a Biotin Blocking System (DAKO Corp.). Slides were incubated 
with Rabbit Anti-human A2BR Antibody (Chemicon, 1:500 dilution, 1 hour room 
temperature). ABC Streptavidin reagents and individual appropriate secondary 
antibodies were used to incubate the sections, and then sections were developed 
with 3, 3'-diaminobenzidine (Sigma-Aldrich) and stained with methyl green. 
Slides were coversliped with Vectashield (Vector Laboratories) mounting 
medium. 
 
Immunocolocalization 
Paraformaldyhyde fixed lung samples were dehydrated, and embedded in 
paraffin, and 5 μm sections were cut and collected on microscope slides. For 
immunofluorescence on tissue sections, rehydrated slides were fixed in 1:1 
acetone-methanol and treated with 1% NaBH4.  Slides were blocked in 1% BSA, 
and incubated overnight at 4°C with the primary antibodies. For 
immunofluorescence on primary human macrophages, cells were cytospun and 
fixed in 3.7% paraformaldehyde in PBS and permeabilized in cold Methanol. 
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Slides were blocked with 1% rabbit serum and incubated overnight at 4°C with 
the primary antibodies. Primary antibodies include: Mouse Anti-human CD73 
Antibody (Hycult Biotechnology, 1:50 dilution), Rabbit Anti-human A2BR Antibody 
(Chemicon, 1:500 dilution), Rat Anti-human MMR (CD206) Antibody (R&D 
Systems, 1:50 dilution).  Sections and cells were incubated with the following 
secondary antibodies: Alexa Fluor 488 rabbit anti-mouse IgG, Alexa Fluor 488 
goat anti-rabbit IgG, Alexa Fluor 568 goat anti-rat IgG (Intritrogen) then 
coversliped with Vectashield with DAPI (Vector Laboratories).   
 
In vitro Stimulation of Human Primary Alveolar Macrophages 
Primary alveolar macrophages were obtained from BAL fluid of Severe 
IPF and Stage 4 COPD patients. BAL fluid was spun and cell pellets were 
resuspended in RPMI1640 containing 10% FBS and 10,000 U/ml 
penicillin/streptomycin. Cells were portioned into aliquots of 2 X 105 cells/well, 
allowed to adhere for 4 hours at 37◦C 5% CO2, and then rinsed twice with 
RPMI1640 without FBS. Cells were either preincubated with 100nM CVT-6883 
(selective A2BR antagonist) for 30 min followed by NECA or incubated with NECA 
alone (in DMSO, 10µM NECA/well; Tocris Bioscience) for 12 h at 37◦C 5% CO2. 
Tissue culture supernatants were collected and IL-8 and IL-6 levels were 
quantitated using Human Quantikine ELISA kits (R&D Systems). 
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Statistics 
As appropriate, groups were compared by analysis of variance; follow-up 
comparisons between groups were conducted using 2-tailed Student’s t test. 
Associations between transcript levels of two genes were established by linear 
regression. Correlation significances were analyzed using Pearson correlation 
calculator software.  Values are expressed as mean ± SEM. A P value of ≤0.05 
was considered to be significant.  
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CHAPTER 3 
ENHANCED AIRWAY INFLAMMATION AND 
REMODELING IN ADENOSINE DEAMINASE-
DEFICIENT MICE LACKING THE A2B ADENOSINE 
RECEPTOR 
 
INTRODUCTION 
 
A2BR Antagonism in ADA-Deficient Mice 
To investigate the contribution of A2BR signaling in the pulmonary 
inflammation and injury observed in ADA-deficient mice, ADA-deficient mice 
were treated with the selective A2BR antagonist CVT-6883. Following the 
treatment, reduced influx of neutrophils and macrophages into the lungs of ADA-
deficient mice was seen and this was associated with decreased expression 
levels of cytokine and chemokine. Meanwhile, the A2BR antagonist treatment also 
resulted in decreased alveolar airspace destruction and diminished expression of 
matrix metalloprotease. Moreover, ADA-deficient mice treated with the antagonist 
showed attenuated pulmonary fibrosis, which was accompanied by decreased 
production of pro-inflammatory and pro-fibrotic mediators such as IL-6, TGF-β1 
and osteopontin. These findings suggest that the activation of the A2BR mediates 
many of the pathological phenotypes seen in the lungs of ADA-deficient mice. 
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Treatment with the antagonist resulted in diminished pulmonary inflammation, 
fibrosis, and airspace enlargement, suggesting that the A2BR plays a pro-
inflammatory, tissue destructive role in this model (57).  
 
Experimental Rationale and Goal 
In addition to the findings in ADA deficient mice, substantial evidence has 
suggested a tissue destructive role of the A2BR. Studies showed that 
engagement of the A2BR promotes the differentiation of pulmonary fibroblasts 
into myofibroblasts and hence increases the deposition of collagen and fibrosis 
(30). Engagement of the A2BR can mediate the direct expression of pro-
inflammatory cytokines such as IL-8, IL-4 and IL-13 from human HMC-1 mast 
cells (53, 55). However, these findings are in contrast to recent studies in A2BR 
knockout mice. The ablation of the A2BR causes low-grade inflammation and 
enhanced leukocyte adhesion to the vasculature (58). In mouse models of 
hypoxia and ventilator-induced pulmonary injury, treatment with an A2BR-
selective antagonist in wild type mice resulted in enhanced pulmonary edema, 
inflammation, and attenuated gas exchange. Similar findings were observed in 
mice with genetic deletion of the A2BR gene, where A2BR-/- mice showed 
increased pulmonary damage following acute injuries. Moreover, A2BR agonist 
treatment could attenuate the pulmonary damage and reverse injury (14, 15, 39). 
These findings indicate that adenosine and A2BR signaling play a critical role in 
the maintenance of pulmonary barrier function. In addition, loss of this Gs-
coupled receptor on mouse bone marrow-derived mast cells results in decreased 
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levels of cAMP and enhanced mast cell activation (59). In order to further 
investigate the role of the A2BR, we genetically removed the A2BR from ADA-
deficient mice to further characterize the function of the A2BR in adenosine-
mediated pulmonary injury and tissue remodeling. Results indicate that the 
genetic removal of A2BR from ADA-deficient mice leads to the exacerbation of 
pulmonary disease, which suggests a critical role for this receptor in protecting 
pulmonary disorders where elevated adenosine levels are involved. 
 
RESULTS 
Elevated A2BR Expression in the Lungs of ADA-Deficient Mice 
In order to determine if there is enhanced A2BR signaling in ADA-deficient 
mice, levels of A2BR transcripts in the lungs of ADA-deficient (ADA-/-) mice was 
determined by semiquantitative RT-PCR. A2BR transcripts were detectable in the 
lungs of ADA-containing (ADA+) and ADA-/- mice, which was significantly 
elevated in the lungs of ADA-/- mice (Figure 3.1A). Quantitative RT-PCR was 
used to confirm these findings. A mean 2.5-fold increase of A2BR transcripts in 
whole-lung RNA extracts was observed in ADA-deficient mice (Figure 3.1B). 
These findings demonstrate that A2BR transcripts are elevated in the lungs of 
ADA-/- mice. 
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Figure 3.1 
The expression of A2BR in the lungs of ADA-/- mice. (A) Transcript levels for 
the A2BR were measured in whole lung mRNA extracts from ADA-containing 
(ADA+) and ADA-deficient (ADA-/-) mice on postnatal day 18, using 
semiquantitative RT-PCR. Findings from 2 different pairs of littermates are 
shown. RNA extracted from the colon of an ADA+ mouse was used as a 
positive control, and β-actin was used as an RNA-positive control for each 
sample. M, DNA size ladder. (B) Quantitative RT-PCR was used to determine 
the levels of A2BR transcripts in day 18 whole-lung extracts from ADA+ and 
ADA-/- mice. Data are presented as mean percentage of β-actin transcripts ± 
SEM; n = 4 for each. *p≤0.05 compared to ADA+.  
Hayes 
Young 
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ADA/A2BR Double Knockout Mice Exhibit Enhanced Pulmonary Pathology 
and Die Precociously 
ADA-/- mice were mated with A2BR-/- mice to generate ADA/A2BR double 
knockout mice to assess the effect of genetically removing A2BR on the 
pulmonary phenotypes seen in ADA-/- mice. ADA-/- mice develop progressive 
pulmonary inflammation and die between postnatal day 18-21 (47). ADA/A2BR 
double knockout mice did not survive past postnatal day 11-12 (data not shown). 
These findings demonstrate that genetic removal of the A2BR from ADA-/- mice 
leads to precocious lung injury and death. The death of animals at such a young 
age made detailed assessment of pulmonary phenotypes difficult. In order to 
circumvent this problem, ADA-/- mice and ADA/A2BR double knockout mice were 
maintained on exogenous ADA enzyme therapy from birth and for the first 21 
days of life and examined following the removal of ADA enzyme therapy. ADA-/- 
mice treated in this manner exhibit signs of respiratory distress approximately 16 
days after the cessation of ADA enzyme therapy. In contrast, ADA/A2BR double 
knockout mice began to show signs of respiratory distress as early as day 11 
after the cessation of enzyme therapy, and this labored breathing became 
increasingly severe up to the death of the animals around postnatal day 16. 
Therefore, detailed phenotype analysis was conducted 14 days after the 
cessation of ADA enzyme therapy. At this stage, ADA-/- mice had diffuse 
monocytic inflammation when compared to that seen wild type mice (Figure 
3.2C). There was no evidence of inflammation in ADA+A2BR-/- mice (Figure 3.2B)  
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Figure 3.2 
Histopathology of the lungs. Lungs were collected on postnatal day 35 and 
prepared routinely for sectioning and H&E staining. (A) Lung section from an 
ADA+A2BR+/+ mouse. (B) Lung section from an ADA+A2BR-/- mouse. (C) Lung 
section from an ADA-/-A2BR+/+ mouse. (D) Lung section from an ADA-/-A2BR-/- 
mouse. Sections are representative of 6–8 different mice from each genotype. 
Scale bars=100 μm. 
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while enhanced pulmonary inflammation and increased congestion of the alveoli 
were observed in ADA/A2BR double knockout mice (Figure 3.2D). 
 
Enhanced Pulmonary Inflammation in ADA/A2BR Double Knockout Mice  
To quantify the level of inflammation in ADA/A2BR double knockout mice, 
bronchial alveolar lavage (BAL) was performed and cells recovered from BAL 
Fluid were counted on a hemacytometer. There was a significant increase in the 
number of inflammatory cells recovered from ADA/A2BR double knockout mice 
compared to that seen in the lungs of ADA-/- mice containing the A2BR (Figure 
3.3A). Differential staining of recovered airway cells demonstrated a significant 
increase in neutrophils and lymphocytes as well as alveolar macrophages. Many 
of these macrophages were activated and enlarged to form foam cells (Figure 
3.3, B and C). To better visualize the increase in lung neutrophilia, lung sections 
were immunostained using an antibody against mouse neutrophils. There were 
robust increases in tissue neutrophils in the lung parenchyma of ADA/A2BR 
double knockout mice compared to ADA-/- mice (Figure 3.3, D and E). Taken 
together, these data suggest that enhanced pulmonary inflammation is seen in 
the lungs of ADA-/- mice lacking the A2BR. 
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 Figure 3.3 
Pulmonary inflammation. (A) BAL fluid was collected on postnatal day 35 and 
total cell numbers were determined. (B) BAL cells were cytospun and stained 
with Diff-Quick, allowing for determination of cellular differentials. Data are mean 
cell counts ± SEM. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+ 
mice; n = 6 (ADA+), 8 (ADA-/-). (C) Cytospun BAL cells stained with Diff-Quick. 
Scale bars=10 μm. (D) Lung section from an ADA-/-A2BR+/+ mouse and an ADA-/-
A2BR-/- mouse (E) were stained with an antibody against neutrophils to visualize 
infiltrated tissue neutrophils (brown). Scale bars=100 μm. 
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Inflammatory Cytokine and Chemokine Production Is Enhanced in 
ADA/A2BR Double Knockout Mice 
In order to better understand the mechanisms involved in the regulation of 
inflammatory responses in ADA/A2BR double knockout mice, transcript levels of 
cytokines and chemokines were monitored in whole-lung RNA extracts. TNF-α 
transcript levels were elevated in the lungs of ADA-/- mice, and they were further 
elevated in the absence of the A2BR (Figure 3.4A). IL-6 transcripts were elevated 
in the lungs of ADA-/- mice. Surprisingly, they were significantly decreased with 
the removal of the A2BR (Figure 3.4B). Levels of chemokines were also 
examined, levels of monocyte chemotactic protein-1 (MCP-1) and CXCL-1 were 
found to be significantly increased in the lungs of ADA-/- mice and levels of 
CXCL-1 were further elevated after the genetic removal of the A2BR (Figure3.4, C 
and D). These data indicate that removal of the A2BR results in exaggerated 
transcription of TNF-α and CXCL-1 in the lungs of ADA-/- mice,whereas selective 
removal of A2BR leads to decreased IL-6. Additionally, cytokine and chemokine 
protein levels were determined in plasma and BAL fluid using the Milliplex mouse 
cytoline/chemokine panel (Table 3.1). Plasma cytokine and chemokine protein 
levels were measured to determine the status of systemic inflammation. CXCL-1 
and MCP-1 protein levels were elevated in the plasma of ADA-/- mice, and levels 
were significantly elevated after the genetic removal of the A2BR. Levels for IL-1α 
and IL-1β were not elevated in ADA-/- mice containing the A2BR; however, they 
were significantly increased in ADA/A2BR double knockout mice. Interestingly, 
MIG protein levels were decreased in the plasma of ADA-/- mice and were further  
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 Figure 3.4 
Production of proinflammatory cytokines. Transcript levels of various 
proinflammatory cytokines were measured in whole-lung extracts from postnatal 
day 35 mice using quantitative RT-PCR. Shown are levels of (A) TNF-α, (B) IL-6, 
(C) CXCL1, (D) MCP-1. Results are presented as mean fold increase compared 
to controls or mean pg transcript/μg RNA ± SEM. *p ≤ 0.05 versus ADA+ mice; #p 
≤ 0.05 versus ADA-/-A2BR+/+ mice.  n = 4 (ADA+), 8 (ADA-/-).  
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 Table 3.1 Cytokine and Chemokine Protein Levels in Plasma and BAL Fluid 
 
 Plasma (pg/ml) BALF (pg/ml) 
 ADA+A2BR+/+ ADA+A2BR-/- ADA-/-A2BR+/+ ADA-/-A2BR-/- ADA+A2BR+/+ ADA+A2BR-/- ADA-/-A2BR+/+ ADA-/-A2BR-/- 
CXCL-1 111±10 155±18 493±121* 1086±191# 3±1 5±1 50±24* 116±29# 
MCP-1 7±1 11±4 27±8* 190±98# 18±16 26±14 153±83* 245±85 
LIF ND ND ND ND 0.3±0.2 0.1±0.1 9±4* 26±8# 
RANTES 18±4 25±4 18±6 20±4 0.4±0.3 0.2±0.1 0.6±0.2 2±1# 
MIG 143±21 123±8 41±14* 19±3 ND ND ND ND 
IL-1α 89±19 52±6 68±37 522±218# 4±1 5±2 2±1 3±2 
IL-1β 17±4 26±4 33±7 81±29# 5±2 4±1 5±1 5±1 
 
Levels of inflammatory mediators in plasma and BAL fluid. Plasma and BAL fluid were 
collected from postnatal day 35 mice. Protein levels of inflammatory cytokines and 
chemokines were determined by luminex assay. Data are presented as mean ± SEM. 
*p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+ mice. n = 4 (ADA+), 6 
(ADA-/-). ND, not detected.  
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decreased in ADA/A2BR double knockout mice. BAL fluid protein levels were 
used to examine cytokines and chemokines in these mice. Levels of CXCL-1 and 
LIF-1 were elevated in the lungs of ADA-/- mice, and levels were significantly 
elevated after the genetic removal of the A2BR. RANTES protein levels were not 
changed in the BAL fluid of ADA-/- mice containing the A2BR; however, they were 
significantly elevated in ADA-/- mice lacking the A2BR. MCP-1 protein levels were 
not changed after the genetic removal of the A2BR though they were increased in 
ADA-/- mice compared to wild type mice. These data suggest that the A2BR 
differentially regulates the expression of cytokines and chemokines where 
elevated adenosine level is involved. 
 
Expression of Cell Adhesion Molecules in the Absence of the A2BR 
It has been demonstrated that the removal of the A2BR is associated with 
the activation of NF-κB pathways as indicated by down-regulation of the NF-κB 
inhibitor IκB-α, and hence the up-regulation of adhesion molecules such as E-
selectin, P-selectin, and ICAM-1 (58). Increased expression of cell adhesion 
molecules is the potential underlying mechanism for the adhesion of leukocytes 
to blood vessels and the migration to sites of infection in the tissue. Based on the 
fact that more infiltrated neutrophils were found in the lung of ADA/A2BR double 
knockout mice compared to that in ADA-/- mice, we examined the expression 
levels of adhesion molecule as well as IκB-α. Whole lung extracts from postnatal 
day 22 and day 35 mice were subjected to Western Blot analysis to determine  
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Figure 3.5 
Western blot analysis of E-selectin, ICAM-1 and IκB-α in whole lung extracts. 
Samples from postnatal day 22 (A) and postnatal day 35 (B) mice were subjected 
to Western blotting with the indicated antibodies. Probing with anti-actin was used 
as loading controls. 
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the protein levels of E-Selectin, ICAM-1 and IκB-α. Day 22 was examined 
because it is a stage when adenosine levels are not elevated in ADA-/- mice and 
it is a stage that precedes the appearance of phenotypes. The expression of E-
Selectin, ICAM-1 and IκB-α were not altered in all genotypes compared to the 
controls on day 22 (Figure 3.5A). However, on day 36 when the disease status is 
established and adenosine levels are high, the expression of E-Selectin and 
ICAM-1 were elevated in  ADA-/- mice and ADA/A2BR double knockout mice,  
though there was no apparent difference in the level of expression with or without 
the A2BR (Figure 3.5B). In addition, the expression of IκB-α was not altered in all 
genotypes (Figure 3.5, A and B). These data demonstrate that there is no 
baseline activation of NF-κB and increased expression of cell adhesion 
molecules in the lung in the absence of the A2BR. The increased expression of 
these adhesion molecules lead to the inflammation seen in ADA-/- mice but 
enhanced tissue neutrophilia in ADA/A2BR double knockout mice compared to 
that in ADA-/- mice is likely not due to enhanced neutrophil adhesion. 
 
Enhanced Vascular Permeability in ADA/A2BR Double Knockout Mice 
Previous studies have shown a central role of the A2BR in the preservation 
of endothelial barrier functions during hypoxia (14). We hypothesized that A2BR 
deficiency would significantly influence vascular leakage in ADA-/- mice. To 
assess this, BAL fluid was collected from postnatal day 35 mice and total protein 
levels were determined. Total protein content was elevated in the lungs of ADA-/-  
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 Figure 3.6 
Vascular permeability analysis. (A) BAL fluid was collected from postnatal day 35 
mice and total BALF protein levels were determined by Bradford assay. Data are 
mean total protein content ± SEM. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus 
ADA-/-A2BR+/+ mice. n = 6 (ADA+), 8 (ADA-/-). (B) Lungs from postnatal day 35 
mice were collected and lung water content was determined by lung wet-dry 
weight ratio. Data are mean ratio ± SEM. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 
versus ADA-/-A2BR+/+ mice. n = 4 (ADA+), 6 (ADA-/-). Mice were administered 
intraperitoneal Evan blue dye (0.2 mL of 0.5% in PBS) and sacrificed 4 hours 
later and the hearts and lungs were harvested. (C) Representative images of 
lungs. Evan blue dye concentrations were quantified in heart (D) and lung (E) as 
described in "Methods". Data are mean dye content ± SEM. *p ≤ 0.05 versus 
ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+ mice. n = 4 (ADA+), 6 (ADA-/-). 
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mice, and increases were markedly enhanced in the absence of the A2BR (Figure 
3.6A). Lung water content was determined by measuring lung wet-dry weight 
ratio. ADA deficiency was associated with a significant degree of lung water 
increase. However, this increase was not affected by the genetic removal of the 
A2BR (Figure 3.6B). However, comparative analysis of vascular permeability as 
assessed by Evans blue dye extravasation revealed that vascular leakage was 
significantly increased in lungs of ADA/A2BR double knockout mice compared to 
that in ADA-/- mice (Figure 3.6, C and E). Basal permeability in ADA+ mice was 
not altered with or without the A2BR (Figure 3.6, D and E). These findings 
demonstrate that signaling through the A2BR is a critical control point for 
pulmonary endothelial barrier function associated with elevated levels of 
adenosine in ADA-/- mice. 
Enhanced Mucous Cell Metaplasia in the Lungs of ADA/A2BR Double-
knockout Mice  
One of the prominent features seen in the bronchial airways of ADA-/- mice 
is mucous cell metaplasia. To determine what impact genetically removing the 
A2BR had on mucous cell metaplasia, tissue sections were stained with PAS, and 
mucous cell metaplasia was quantitated by morphometry. In the bronchial 
airways, A2BR-/- mice showed increased numbers of PAS-positive cells (Figure 
3.7, A, B, and E). As expected, in the bronchial airways of ADA-/- mice, a large 
number of mucin-containing cells were observed (Figure 3.7, C and E). 
Moreover, in the bronchial airways of ADA/A2BR double knockout mice, there was  
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 Figure 3.7 
Mucus metaplasia. On postnatal day 35, lungs were collected and prepared for 
sectioning and PAS staining. (A), Lung section from an ADA+A2BR+/+ mouse. 
(B), Lung section from an ADA+A2BR–/– mouse. (C), Lung section from an ADA–
/–A2BR+/+ mouse. (D), Lung section from an ADA–/–A2BR–/– mouse. Sections are 
representative of eight different mice from each genotype. Bars, 100 µm. (E), 
Mucus index was determined, and data are presented as mean mucus index ± 
SEM. *, p 0.05 vs ADA+ mice; #, p 0.05 vs ADA–/–A2BR+/+ mice. n = 4 
(ADA+A2BR+/+ and ADA+A2BR–/–), n = 8 (ADA–/–A2BR+/+ and ADA–/–A2BR–/–). 
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Figure 3.8  
Mucin Gene Expression. Whole lung RNA extracts were analyzed using 
quantitative RT-PCR assays for Muc5ac (A), Muc5b (B) and Clca3 (C). Results 
are presented as mean fold increase compared to controls ± SEM. *p ≤ 0.05 
versus ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+ mice.  n = 4 (ADA+), 8 (ADA-/-). 
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increased PAS staining (Figure 3.7, D and E). These results demonstrate that 
mucin accumulated in A2BR-/- mice at baseline and that mucus metaplasia is 
enhanced in ADA/A2BR double knockout mice. 
 Major mucin gene transcripts levels were quantitated by Real-time PCR. 
Interestingly, although mucus metaplasia was enhanced in ADA/A2BR double 
knockout mice, there were decreases in levels of expression of the major mucins, 
Muc5ac (Figure 3.8A), and Muc5b (Figure 3.8B), and the mucous metaplasia 
marker calcium-activated chloride channel 3 (Clca3) (Figure 3.8C). This finding 
suggests that the A2BR may play an important role in mucin secretion. Although 
mucin gene expression is decreased in the double-knockout mice compared to 
ADA-deficient mice, the defect in mucociliary clearance lacking the A2BR would 
still result in enhanced mucus accumulation. 
Enhanced Alveolar Destruction in the Lungs of ADA/A2BR Double Knockout 
Mice 
ADA-/- mice develop characteristics of emphysema  and features of 
alveolar airspace enlargement (47). To determine whether A2BR was involved in 
mediating airspace enlargement, alveolar destruction was analyzed in ADA-/- 
mice and ADA/A2BR double knockout mice 14 days after the cessation of 
exogenous ADA enzyme therapy. The size of alveolar airspaces in ADA-/- mice 
showed a significant increase (Figure 3.9, C and E). The degree of airspace  
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Figure 3.9 
Alveolar airspace enlargement. Lungs from postnatal day 35 mice were 
infused with fixative under constant pressure (25 cm H2O) and processed for 
H&E staining. (A) Lung section from an ADA+/A2BR+/+ mouse. (B) Lung section 
from an ADA+A2BR-/- mouse. (C) Lung section from an ADA-/-A2BR+/+ mouse. 
(D) Lung section from an ADA-/-A2BR-/- mouse. Images are representative of 6-
8 animals from each genotype. Scale bars=100 μm. (E) Alveolar airspace size 
was calculated using ImagePro analysis software; data are mean chord length 
± SEM. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus ADA-/-A2BR+/+ mice. n = 
4 (ADA+), 6 (ADA-/-). 
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 Figure 3.10 
TUNEL Staining. (A) TUNEL-stained lung section from an ADA-/- mouse. (B) 
TUNEL-stained lung section from an ADA-/-A2BR-/- mouse. Images are 
representative of eight animals from each genotype. (C), TUNEL-positive cells 
were counted, and data are presented as mean TUNEL scores ± SEM. *, p 
0.05 vs ADA+ mice; #, p 0.05 vs ADA–/–A2BR+/+ mice. n = 4 (ADA+A2BR+/+ and 
ADA+A2BR–/–), n = 8 (ADA–/–A2BR+/+ and ADA–/–A2BR–/–). Bars = 100 µm. 
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Figure 3.11 
Collagen production. (A) Whole lung α1-pro-collagen transcript levels were 
measured from postnatal day 35 mice using quantitative RT-PCR, and data are 
presented as mean fold increase compared with controls or mean pg 
transcript/µg RNA ± SEM. (B), Soluble collagen protein levels in BAL fluid from 
postnatal day 35 mice were quantified using the Sircol assay. Results are 
presented as mean collagen levels ± SEM. *, p 0.05 vs ADA+ mice; #, p 0.05 vs 
ADA–/–A2BR+/+ mice. n = 4 (ADA+A2BR+/+ and ADA+A2BR–/–), n = 8 (ADA–/–A2BR+/+ 
and ADA–/–A2BR–/–). 
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enlargement was further increased in the lungs of ADA/A2BR double knockout 
mice (Figure 3.9, D and E). Consistent with these findings, increased apoptosis 
in the alveolar airspaces of ADA/A2BR double-knockout mice were observed 
compared to ADA  mice (Figure 3.10). This finding demonstrates that there is 
increased alveolar destruction in the lungs of ADA/A2BR double knockout mice. 
tion are 
prominant features noted in the lungs of ADA-/- mice. Examination of the 
transcript levels of α-1 procollagen (Figure 3.11A) and soluble BAL collagen 
levels (Figure 3.11B) revealed enhanced collagen production and signs of 
enhanced pulmonary fibrosis in the lungs of ADA/A2BR double-knockout mice.  
levated 
adenosine levels (65). To determine whether A2BR plays a role in regulating 
tracheal vascularity, CD31 whole mount immunohistochemistry was performed 
on tracheas (Figure 3.12). Consistent with the previous finding, results suggest 
that there are increased numbers of vessel in ADA  mice compared to wide type 
mice. Interestingly, ADA/A2BR double knockout mice exhibited further increased 
tracheal vascularity compared with ADA  mice possessing the A2BR (Figure 
3.12). These results indicate that the genetic removal of the A2BR leads to 
enhanced tracheal angiogenesis in ADA  mice. 
 
-/-
Enhanced Pulmonary Fibrosis in ADA/A2BR Double Knockout Mice 
Enhanced extracellular matrix deposition and collagen produc
Enhanced Tracheal Vascularity in ADA/A2BR Double Knockout Mice 
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-/-
-/-
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Figure 3.12 
Tracheal vascularity and angiogenesis. (A) Tracheas were removed from 
postnatal day 35 mice and angiogenesis was analyzed by whole mount CD31 
immunostaining for the visualization of vessels. Results are representative of 4 
mice from each genotype. Scale bars=100 μm. (B) Tracheal vascularity was 
determined in the samples shown in A by counting the number of vessels 
intersecting a line down the length of the cartilage ring. At least 12 cartilage rings 
were analyzed per sample. Data are represented as mean vessels (in 
millimeters) ± SE; n = 4. *p ≤ 0.05 versus ADA+ mice; #p ≤ 0.05 versus ADA-/-
Amir Mohsenin 
A2BR+/+ mice. 
51 
 
Adenosine Levels in ADA/A2BR Double Knockout Mice 
To determine if elevated adenosine levels in ADA/A2BR double knockout 
mice could contribute to the enhanced pulmonary pathology, adenosine levels in 
BAL fluid were quantitated using HPLC. Results suggest that there are increased 
adenosine levels in ADA-/- mice compared to wide type mice. Interestingly, 
adenosine levels were not further elevated in ADA/A2BR double knockout mice 
compared with ADA-/- mice possessing the A2BR (Figure 3.13).  
 
DISCUSSION 
Adenosine can have both tissue-protective and tissue-destructive 
functions depending on endogenous adenosine concentrations generated 
following injury, the nature and duration of injury,  and the expression profile of 
each adenosine receptor on specific cell types (22, 66). Adenosine’s tissue-
destructive role is supported by the ADA-deficient mouse model where elevated 
adenosine levels lead to features of chronic lung disease including inflammation, 
mucin overproduction, alveolar airway enlargement, fibrosis and angiogenesis 
(47, 65). The A2BR is widely expressed in tissues and has been indicated to play 
an important role in inflammation and tissue remodeling. In the current study, 
A2BR was genetically removed from ADA-deficient mice to generate double 
knockout mice to examine the contribution of the A2BR to the pulmonary 
  
 
 
Figure 3.13 
Adenosine levels in BAL fluid. BAL fluid was collected on postnatal day 35 and 
adenosine levels were measured using reversed phase HPLC. Data are
presented as mean nmol adenosine ± SEM. n = 3 for each group. * p ≤ 0.05 
versus ADA+ mice. 
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phenotype seen in ADA-deficient mice. Findings demonstrate that the genetic 
removal of the A2BR from ADA-deficient mice leads to precocious lung injury and 
death. The precocious pulmonary damage and death of these mice was 
associated with increased lung inflammation, vascular permeability, alveolar 
destruction and tracheal angiogenesis. These results demonstrate that the A2BR 
plays an important role in protecting pulmonary inflammation and damage seen 
in ADA-deficient mice.   
One of the major observations in this study was that ADA/A2BR double 
knockout mice exhibited enhanced pulmonary inflammation compared to ADA-
deficient mice possessing the A2BR. There were increases in lymphocytes and 
particularly neutrophils in the BAL fluid of ADA-deficient mice lacking the A2BR. 
Consistent with this, immunostaining showed that there were more neutrophils in 
the lungs of ADA/A2BR double knockout mice compared to ADA-deficient mice, 
icient mice using an A2BR antagonist results in 
diminished pulmonary inflammation (57). The A2BR has been shown to exhibit 
both pro- and anti-inflammatory functions. The first in vivo evidence showing 
A2BR’s anti-inflammatory roles comes from a study where the genetic ablation of 
the A2BR was associated with low-grade inflammation that was associated with 
the augmentation of pro-infammatory cytokines, such as TNF-α, and a 
consequent downregulation of Iκb-α, the inhibitor of NF-κB signaling pathway. In 
this study, the activation of NF-κB was proposed to lead to the expression of pro-
suggesting that A2BR signaling may be protective in regulating pulmonary 
neutrophilia. These findings differ somewhat from our recent observations that 
blockade of the A2BR in ADA-def
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inflammatory cytokines, chemokines and cell adhesion molecules (58). We 
therefore examined whether activation of these pathways might account for the 
increased neutrophil counts seen in the lungs of ADA/A2BR double knockout 
mice. Interestingly, expression levels of cell adhesion molecules such as ICAM-1 
and E-selectin were not altered in the lungs of ADA-deficient mice lacking the 
A2BR, nor was expression of Iκb-α affected. Thus, activation of NF-κB signaling 
pathways and altered adehesion molecule expression do not appear to be 
responsible for enhanced pulmonary inflammation in ADA/A2BR double knockout 
mice.  
 
However, our experiments did reveal an increase in pulmonary vascular 
permeability in the lungs of ADA/A2BR double knockout mice, which may account 
for the increased neutrophil infiltration into the lung. This is consistent with the 
observations that pharmacologic blockade and genetic removal of the A2BR is 
central to hypoxia-associated vascular leak (14). Activation of the A2BR is 
associated with increases in intracellular cAMP concentration following activation 
of PKA. PKA-induced phosphorylation of vasodilator-stimulated phosphoprotein 
(VASP) may result in changes in junctional protein geometry and distribution, and 
hence regulating the characteristics of the junctional complex, leading to barrier 
function increases (3, 67, 68). Hypoxia exposure and ADA deficiency both result 
in a prolonged action of extracellular adenosine and enhanced adenosine 
signaling. Adenosine plays a protective role in controlling vascular leakage that 
mice deficient in enzymes involved in extracellular adenosine generation showed 
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profound increases in vascular leakage (3, 69). Therefore, the genetic removal of 
the A2BR from ADA-deficient mice may lead to enhanced vascular permeability 
and subsequent neutrophil accumulation in the tissue. 
 
Inflammatory cell accumulation in the lung occurs following pro-
inflammatory stimuli that result in the recruitment of cells into tissue from the 
circulatory system. Thus, increased expression levels of inflammatory cytokines 
and chemokines could also contribute to neutrophil infiltration into the lungs. 
Transcript levels of TNF-α and CXCL-1 were elevated in the lungs of ADA-
deficient mice, and levels were markedly increased in the absence of the A2BR. 
Interestingly, IL-6 levels were decreased with the removal of the A2BR, 
suggesting the A2BR regulates the production of IL-6 in this model. Consistent 
with this, engagement of the A2BR increases IL-6 release from bronchial smooth 
muscle cells (70), human lung fibroblasts (30), and airway epithelia (71); while 
adenosine inhibits TNF-α release from mouse peritoneal macrophages and 
human monocytes via the A2BR (72, 73). Additionally, cytokine and chemokine 
protein levels were determined from BAL fluid and plasma to monitor the 
inflammatory status in lung and systemically. As expected, levels of CXCL-1, LIF-
1 and RANTES were elevated in BAL fluid from ADA/A2BR double knockout mice 
compared to that in ADA-deficient mice. Although expression levels of certain 
cytokines and chemokines did increase after the genetic removal of the A2BR 
from ADA-deficient mice, we did not see increased percentage of neutrophils in 
peripheral white blood cell counts (data not shown). As a result, increases in lung 
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neutrophil mumbers appeared to depend largely on enhanced vascular 
permeability following the genetic removal of the A2BR.  
An interesting finding in this study is that mucus metaplasia was enhanced 
in AD /A2BR double-knockout mice, consistent with the other enhanced 
pulmon
A
ary histopathology. However, there was a decrease in degree of 
expression of the major mucin genes and mucous metaplasia marker Clca3. 
Although we cannot rule out the roles of other mucin genes that possibly take 
part in mucus accumulation, this finding suggests that the A2BR may play an 
important role in mucociliary clearance. Previous studies have shown that the 
A2BR is an important regulator of cystic fibrosis transmembrane conductance 
regulator (CFTR) functions and lacking this receptor may lead to dehydration of 
airway surface liquid volume and mucus stasis (74). As a result, even thought 
there was decreased mucin gene expression in the absence of A2BR signaling, 
the defect in mucus clearance would still lead to mucus accumulation in the 
airways. Further studies are needed to clarify the role of the A2BR in mucin gene 
expression as well as mucociliary clearance. 
Another prominent feature of ADA/A2BR double knockout mice was 
enhanced tissue remodeling, including destruction of alveolar airspaces, a 
response reminiscent of emphysema, and trachea angiogenesis (47, 61, 62). 
The degree of the enlargement of airspace was significantly increased in the 
lungs of ADA-deficient mice lacking the A2BR. It is possible that this pulmonary 
phenotype noted in ADA/A2BR knockout mice is attributed to the increases in 
pulmonary neutrophils seen. For example, neutrophils produce degradative 
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enzymes such as matrix metalloproteinase-9 and neutrophil elastase, which can 
contribute to alveolar airway enlargement and could account for the enhanced 
airspac
y till Day 21. Three days after the 
remov
e enlargement seen in ADA/A2BR double knockout mice exhibiting 
increases in airway neutrophils. ADA-deficient mice have increased tracheal 
angiogenesis in association with increased CXCL-1 level (65). Similarly, the 
current study showed that enhanced tracheal vascularity is associated with 
increased CXCL-1 expression seen in the lungs of ADA/A2BR double knockout 
mice. These findings demonstreate that CXCL-1 level in the lung may directly 
regulates pathological angiogenesis and may serve as an important therapeutic 
target. 
 
Overall, ADA/A2BR double knockout mice have enhanced lung 
inflammation and tissue destruction when compared to ADA-deficient mice that 
express the A2BR. These observations contradict those seen in this same model 
following A2BR antagonism (57). In the A2BR antagonism study, ADA-deficient 
mice were kept on Peg-ADA enzyme therap
al of ADA enzyme therapy, the A2BR antagonist CVT-6883 was given 
intraperitoneally. CVT-6883-treated ADA-deficient mice exhibited diminished 
pulmonary inflammation, fibrosis, and alveolar airspace destruction, suggesting 
the pro-inflammatory functions of the A2BR. Clearly, discrepancies exist while 
characterizing the anti- or pro-inflammatory functions of the A2BR. In addition to 
the finding from A2BR antagonism in ADA-deficient mice show A2BR’s tissue-
destructive roles, engagement of the A2BR promotes the differentiation of 
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pulmonary fibroblasts into myofibroblasts and hence increases the deposition of 
collagen and fibrosis (30). A2BR activation also mediates the direct expression of 
pro-inflammatory cytokines such as IL-8, IL-4 and IL-13 from human HMC-1 cells 
(52, 53, 56). Stimulation of A2BRs up-regulates IL-6 production from mouse 
macrophages (75), IL-13 and VEGF secretion from mouse bone marrow mast 
cells (56). Inconsistent with these findings, A2BR plays an anti-inflammatory role 
that tissue damage and injury could be amplified in the absence of A2BR 
signaling. A2BRs are required for airway surface liquid (ASL) volume homeostasis 
in human airways and therapies directed at inhibiting the A2BR may lead to 
depleted ASL volume and mucus stasis (74). The ablation of the A2BR causes 
low-grade inflammation, augmentation of pro-infammatory cytokines, such as 
TNF-α, and a consequent activation of NF-κB signaling pathway (58). Loss of this 
Gs-coupled receptor on mouse bone marrow-derived mast cells results in 
decreased levels of cAMP and enhances mast cell activation (59).  
The functions of A2BR signaling are also controversial in other organs. The 
reno-vascular A2BR protects the kidney from ischemia that ischemic 
preconditioning (IP) protection from ischemia was abolished in A2BR-/- mice while 
treatment with the selective A2BR agonist dramatically improved renal function 
and histology following ischemia injury (76). Blockade or deletion of the A2BR in a 
mouse model of colitis showed reduced clinical symptoms, histological scores, 
IL-6 and KC levels in the supernatants of colonic organ cultures (77, 78). 
Interestingly, although colonic inflammation was attenuated in A2BR-/- mice 
compared with their wild type counterparts, A2BR-/- mice actually showed 
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increased susceptibility to systemic Salmonella infection (77). It seems that in 
most cases pharmacological blockage of the A2BR by antagonists is beneficial 
while gene deletion of the A2BR generally enhances the phenotypes seen in 
multiple organs and systemically after injury. The discrepancies between the 
pharmacological block and gene knockout studies may be related to the nature of 
injury, the specific organ environment, the levels and duration of adenosine 
elevation, and the timing of A2BR antagonism. The A2BR may have a bi-phasic 
effect on inflammation that the A2BR antagonist could be beneficial only when it is 
given after the disease status is established, while the A2BR plays an important 
protective role before the chronic stage of the disease. Moreover, the 
discrepancy between these two studies could be due to the fact that the 
antagonist may only have a partial affect in blocking the receptor activity while 
genetic knockout completely abolishes the receptor signaling. Additionally, it has 
been shown in the literature that the A2BR could be recruited to the plasma 
membrance to form receptor dimers or a complex with other proteins, such as 
ezrin, and compartmentalize E3KARP (79). For this reason, Ryzhov et al. argued 
that mast cell activation and the increase in basal and LPS-stimulated TNF-α 
release observed in A2BR-/- mice is not directly related to adenosine signaling 
through the A2BR, but it may represent a loss of other unidentified functions of 
this protein or reflect a developmental adaptation to the A2BR gene ablation (75). 
 
               In conclusion, the results of the present study demonstrated that the 
genetic removal of the A2BR from ADA-deficient mice enhanced pulmonary 
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inflammation and injury induced by increased adenosine levels. These findings 
are inconsistent with the previous pharmacological study and the hypothesis that 
A2BR signaling contributes to the pro-inflammatory and tissue-destructive 
activities present in chronic lung diseases. The A2BR may have a bi-phasic effect 
on inflammation that the A2BR antagonist may be beneficial only when it is given 
after the disease status is established. Thus, cautions must be taken when 
designing A2BR antagonist treatment strategies in human chronic lung disease. 
The results of the present study demonstrated that the genetic removal of the 
A2BR from ADA-deficient mice resulted in enhanced pulmonary inflammation and 
injury induced by increased adenosine levels. The underlying mechanism for 
enhanced tissue damage is thought to be excessive neutrophil infiltration caused 
by loss of pulmonary vascular barrier function. These findings suggest that during 
the acute stage of lung injury, A2BR plays a homeostatic and protective role such 
as barrier function, but it plays a detrimental role during the chronic stage of 
diseases such as pulmonary fibrosis. Moreover, inhibition of the A2BR may result 
in collapsed airway surface liquid and mucus stasis that could potentially 
accentuate disease status. Further studies are needed to understand the 
complicated role of the A2BR, which will be critical for developing A2BR-based 
therapies for the treatment of various diseases. In the next chapter, specific 
experiments were designed to determine the potential mechanisms of the 
destructive and protective components of A2BR signaling. 
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CHAPTER 4 
THE ROLE OF THE A2BR IN ACUTE AND CHRONIC 
STAGES OF BLEOMYCIN-INDUCED LUNG 
INJURY 
 
In the previous chapter, I demonstrated that the genetic removal of the 
A2BR from ADA-deficient mice results in enhanced pulmonary inflammation, 
fibrosis and alveolar airspace enlargement. Enhanced pulmonary vascular 
permeability due to the lack of the A2BR may be responsible for the increased 
damage in the lung. This finding, together with the previous findings that A2BR 
signaling promotes the expression of pro-inflammatory and pro-fibrotic mediators 
(32, 53, 57), suggests that A2BR plays a protective role during the acute phase of 
lung injury and promotes destructive features during chronic stages of the 
disease. Studies described in this chapter focus on understanding the distinctive 
roles of the A2BR at different stages of lung injury in another model of pulmonary 
injury: the model of bleomycin-induced pulmonary injury. 
 
INTRODUCTION 
Bleomycin induced pulmonary fibrosis 
Pulmonary fibrosis is characterized by extracellular matrix deposition, 
errant fibroblast proliferation, and inflammation, which are distinctive features ab
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of interstitial lung diseases. odeling processes result in 
distortion of lung architecture and compromised pulmonary function (10). 
verticil ically 
generating double strand DNA breaks and results in apoptosis of affected cells 
(80). The expression of bleom e, the enzyme that degrades 
bleomycin, is particularly low in the lung and skin (81). As a result, the most 
serious side effect of bleomycin is pulmonary fibrosis and impaired lung function 
(82). About 1% of patients suffer from irreversible pulmonary fibrosis following 
bleomycin exposure (83).  
This side effect has been used to investigate the mechanisms of fibrosis. 
Bleomycin results in similar lung parenchyma injury and interstitial fibrosis in 
mice as is seen in humans (84). Lungs that have been exposed to bleomycin 
show evidence of injury and inflammation, which involves an infiltration of 
granulocytes, lymphocytes and monocytes (85). Ultimately, increased deposition 
of extracellular matrix such as collagen and fibronectin in the alveolar wall 
compromise pulmonary function (86, 87). Pulmonary injury in mice induced by 
bleomycin delivered intratracheally or intraperitoneally are two well-established 
animal models of lung fibrosis (88, 89); however, the route of delivery results in 
different degrees of acute injury. 
  
 
 
These tissue rem
Bleomycin is a glycopeptide antibiotic produced by the bacterium Streptomyces 
lus and is a widely used anti-cancer agent. It functions by catalyt
ycin hydrolas
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IT versus IP bleomycin treatment 
In the standard intratracheal (IT) bleomycin induced pulmonary injury 
model, 10-week old female mice are exposed to a single dose of 2.5 U/kg 
bleomycin IT. Mice develop significant pulmonary fibrosis at 21 days after 
challenge. However, since bleomycin is instilled directly into the respiratory tract, 
the acute damage caused by bleomycin results in extensive apoptosis of airway 
epithelial cells, followed by an acute phase of pulmonary injury resulting in a 
large amount of infiltrating granulocytes around Day 7 after the challenge. Most 
granulocytes are resolved by Day 21 and macrophages and lymphocytes remain 
in the airways. At this stage, mice develop severe fibrosis due to a failed wound 
healing
xperimental Rational and Goals 
In the previous studies, when ADA-deficient mice were treated with the 
2BR antagonist 3 days after the cessation of Peg-ADA treatment, they showed 
 response. In contrast, in the intraperitoneal (IP) bleomycin model, 6-week 
old male mice are treated with a higher dose of bleomycin IP twice a week for 
four weeks. Since drug is delivered systemically into the peritoneal cavity and the 
lung is not directly exposed to bleomycin directly, there is not excessive acute 
injury or inflammation in the lung. However, when mice are sacrificed a week 
after the last treatment on day 33, they do develop a significant amount of 
pulmonary fibrosis.  
Thus, IT bleomycin is a model of acute injury, followed by fibrosis, and IP 
bleomycin is a model of mild injury and progressive pulmonary fibrosis.    
 
E
A
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less pulmonary inflammation, fibrosis, and alveolar airspace enlargement 
compa
ute injury and inflammation will be observed in A2BR-/- mice 
due to
e when 
ssessing fibrosis at Day 21 endpoint in the IT model.  
 
red to ADA-deficient mice, suggesting pro-inflammatory and pro-fibrotic 
functions of the A2BR. However, the genetic removal of the A2BR from ADA-
deficient mice resulted in significantly enhanced pulmonary inflammation, fibrosis 
and alveolar airspace enlargement, in which enhanced pulmonary vascular 
permeability due to the lack of A2BR likely played an important role. As a result, 
these studies provide the proof of concept that the A2BR is fundamental in 
maintaining vascular barrier function during the acute phase of pulmonary injury, 
while it is tissue-destructive during the chronic phase.   
In order to further address this concept in another model of pulmonary 
injury, we took the genetic approach to investigate the role of A2BR in the model 
of bleomycin-induced pulmonary injury. We utilized the two different drug delivery 
methods described above to determine the functions of the A2BR at different 
stages of lung injury. We hypothesized that in the IP bleomycin model, since no 
acute damage and inflammation are involved, A2BR-/- mice will show significantly 
less pulmonary fibrosis compared to wild type mice; however, in the IT bleomycin 
model, enhanced ac
 their compromised vascular barrier function. This may counteract the pro-
fibrotic functions of the A2BR and there will not be a significant differenc
a
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RESULTS 
Fibrosis in the IT bleomycin model 
To determine the role of the A2BR in IT bleomycin-induced pulmonary 
injury, wild type and A2BR-/- mice were exposed to a single dose of 2.5 U/kg 
bleomycin IT and fibrosis was assessed 21 days after bleomycin exposure. Mice 
exposed to saline were used as controls and they showed no sign of fibrosis on 
Day 21 (Figure 4.1, A and C). Mice exposed to bleomycin exhibited significant 
pulmonary fibrosis and extracellular matrix deposition; however, there did not 
appear to be a difference in pulmonary histopathology when comparing wild type 
mice (
posure affects the role of 
e A2BR in bleomycin-induced injury, mice were treated with 8 doses of 
leomycin IP twice a week for 4 weeks. Fibrosis was assessed a week after the 
st bleomycin exposure. Mice exposed to PBS were used as controls and  
Figure 4.1B) to A2BR-/- mice (Figure 4.1D) exposed to bleomycin. To 
assess the degree of fibrosis in these mice, the Sircol assay was used to 
measure soluble collagen in BAL fluid, and Ashcroft scores were determined on 
lung sections. Analysis showed that bleomycin exposure resulted in the same or 
slightly decreased degree of fibrosis in A2BR-/- compared to wild type mice (Figure 
4.1, E and F). These results suggested that, surprisingly, the genetic removal of 
the A2BR did not lead to diminished nor enhanced development of pulmonary 
fibrosis in the IT model. 
 
Fibrosis in the IP bleomycin model  
To investigate whether the route of bleomycin ex
th
b
la
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Figure 4.1 
Histopathology of the lungs. Lungs were collected 21 days after bleomycin exposure and 
prepar 2BR+/+ 
mouse treated with saline. (B) Lung section from an A R+/+ mouse treated with 
ction 
from an A R-/- mouse treated with bleomycin. Sections are representative of 6-8 
 was 
conducted to determine the extent of fibrosis. (E) Soluble collagen protein levels in BAL 
an collagen 
levels ± SEM. *, p 0.05 vs ADA+ mice treated with saline; #, p 0.05 vs A2BR+/+ mice 
treated with bleomycin. n = 6 (saline treated), n = 8 (bleomycin treated). 
ed routinely for sectioning and H&E staining. (A) Lung section from an A
2B
bleomycin. (C) Lung section from an A2BR-/- mouse treated with saline. (D) Lung se
2B
different mice from each genotype. Scale bars = 100 μm. (D) Ashcroft scoring
fluid were quantified using the Sircol assay. Results are presented as me
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Figure 4.2 
logy of the lungs. Lungs were collected 33 days after the first bleomycin Histopatho
exposure and prepared routinely for sectioning and H&E staining. (A) Lung 
section from an A2BR+/+ mouse treated with PBS. (B) Lung section from an A2BR+/+ 
mouse treated with bleomycin. (C) Lung section from an A2BR-/- mouse treated 
with PBS. (D) Lung section from an A2BR-/- mouse treated with bleomycin. 
Sections are representative of 6-8 different mice from each genotype. Scale bars 
= 100 μm. (D) Ashcroft scoring was conducted to determine the extent of fibrosis. 
(E) Soluble collagen protein levels in BAL fluid were quantified using the Sircol 
assay. Results are presented as mean collagen levels ± SEM. *, p 0.05 vs ADA+ 
mice treated with PBS; #, p 0.05 vs A2BR+/+ mice treated with bleomycin. n = 6 
(saline treated), n = 8 (bleomycin treated). 
showed no signs of fibrosis (Figure 4.2, A and C). In contrast, wild type mice 
exposed to bleomycin exhibited significant pulmonary fibrosis and extracellular 
matrix deposition (Figure 4.2B). Interestingly, A2BR-/- mice exposed to bleomycin 
had a diminished degree of fibrotic histopathology compared to wild type mice 
(Figure 4.2D). To quantitate the degree of fibrosis in these mice, Ashcroft Scoring 
was conducted and revealed that A2BR-/- had diminished fibrosis compared to 
wild type mice (Figure 4.2E). The Sircol assay confirmed that levels of soluble 
collagen in BAL fluid are significantly lower in A2BR-/- mice compared to that in 
wild type mice (Figure 4.2F). These results suggested that the genetic removal of 
the A2BR resulted in diminished pulmonary fibrosis in the IP model of bleomycin-
induced pulmonary injury. 
 
Inflammation in the IT and IP bleomycin models 
To examine the effects of the A2BR on pulmonary inflammation following 
bleomycin-induced injury, the numbers of inflammatory cells recovered from BAL 
fluid were quantitated at both the acute and chronic phase to determine the 
status of pulmonary inflammation at early and late stages of the disease.  
 IT bleomycin model, direct damage to the lung results in an acute 
i
n
b
s
C
In the
nflammation. Indeed, our findings suggest that the total inflammatory cell 
umbers recovered from BAL fluid was significantly increased 7 days after 
leomycin exposure. Interestingly, the number of total inflammatory cells was 
ignificantly higher in A2BR-/- compared to wild type mice (Figure 4.3A, left panel). 
ell differentials suggested that increased numbers of macrophages and 
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neutrophils were responsible for the total cell number increase. In animals 
treated with bleomycin, the most significant difference between A2BR-/- mice and 
wild type mice was that there were more infiltrated neutrophils in A2BR-/- mice 
(Figure 4.3A, middle and right panels). At the chronic phase of the IT bleomycin 
model, we still observed an increase in total cell number in mice treated with 
bleomycin on Day 21. However, there was no difference in the number of total 
cells between wild type and A2BR-/- mice (Figure 4.3B, left panel). Moreover, the 
numbers of macrophages, lymphocytes and neutrophils were not altered in A2BR-
/- mice compared to wild type animals (Figure 4.3B, middle and right panels). This 
is consistent with our observation that there was no difference in fibrosis between 
wild type and A2BR-/- mice. These findings suggest that IT bleomycin treatment in 
2BR-/- mice is associated with enhanced acute pulmonary inflammation and 
ereas lacking the A2BR at the 
chronic
umber 
of tota
A
neutrophil infiltration compared to wild type mice, wh
 phase has no effect on pulmonary inflammation. 
Examination of pulmonary inflammation in the IP bleomycin model was 
also determined by counting the number of inflammatory cells recovered from 
BAL fluid. At 10 days after the initiation of IP bleomycin treatments, the n
l inflammatory cells was significantly increased. However, there was no 
difference in the number of total cells between wild type and A2BR-/- mice (Figure 
4.3C, left panel). Cell differentials suggested that most cells recovered were 
macrophages. Importantly, there was no increased neutrophil infiltration in this 
model. Moreover, there was no difference in the numbers of each cell types 
between wild type and A2BR-/- mice (Figure 4.3C, middle and right panels). At the 
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chronic phase of the IP bleomycin model, an increase in total cell number on Day 
33 was also observed in mice treated with bleomycin. However, there was no 
difference in the numbers of total cells and macrophages between wild type and 
A2BR-/- mice (Figure 4.3D, left and middle panels). Interestingly, the numbers of 
lymphocytes and neutrophils were significantly decreased in A2BR-/- mice 
compared to wild type mice (Figure 4.3D, right panel). These findings suggest 
that the IP bleomycin treatment was not associated with an acute inflammation 
and neutrophil infiltration at the acute phase; even though decreased pulmonary 
fibrosis was observed in A2BR-/- mice compared to wild type mice following 
bleomycin exposure, lacking the A2BR at the chronic phase had only mild effect 
on pulmonary inflammation. 
 
Vascular permeability in the IT and IP bleomycin models 
Acute lung injury is commonly associated with the loss of pulmonary 
vascular barrier function, which can contribute to enhanced neutrophil infiltration 
into the lung. Previous studies have shown that the A2BR plays a protective role 
in the maintenance of pulmonary barrier function in various models of acute lung 
injury (14, 39). Findings in chapter 4 of this dissertation suggest that the 
enhanced loss of vascular barrier function in ADA/A2BR double knockout mice 
resulted in enhanced pulmonary inflammation. Here I show that the IT bleomycin 
model where an acute damage is involved, there is an increase in the number of 
infiltrated inflammatory cells, specifically neutrophils, in A2BR-/- mice compared to 
wild type mice at the acute phase of the injury. To determine if the loss of  
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Figure 4.3 
collected 7 days after  IT bleomycin exposure. (B) BAL fluid was collected 21 d
exposure. (D) BAL fluid was collected 33 days after IP bleomycin exposure. Total 
Quick, allowing for determination of cellular differentials. Data are mean ce
Pulmonary inflammation in the IT and IP bleomycin models. (A) BAL fluid was 
ays 
after IT bleomycin exposure. (C) BAL fluid was collected 10 days after IP bleomycin 
cell 
numbers were determined. Then BAL cells were cytospun and stained with Diff-
ll counts ± 
SEM. *p ≤ 0.05 versus mice treated with saline or PBS; #p ≤ 0.05 versus A2BR+/+ mice 
treated with bleomycin; n = 8. 
  
 
 
 
Figure 4.4 
Vascular permeability in the IT and IP bleomycin models. (A) 7 days after IT 
bleomycin exposure or 10 days after the first IP bleomycin exposure, mice 
were administered intraperitoneal Evan blue dye (0.2 mL of 0.5% in PBS) and 
sacrificed 4 hours later. Lungs were harvested and Evan blue dye 
concentrations were quantified as described in "Methods". (B) Representative 
images of lungs. Data are mean dye amount ± SEM. *p ≤ 0.05 versus mice 
treated with saline or PBS; #p ≤ 0.05 versus A2BR+/+ mice treated with 
bleomycin; n = 6. 
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vascular barrier occurs in A2BR-/- mice, Evans blue dye extravasations were 
quantitated four hours after injecting the dye intraperitoneally. Results revealed 
that there was enhanced vascular leakage in A2BR-/- mice compared to that in 
wild type mice after bleomycin induced injury (Figure 4.4, A and B). In contrast, 
there was only mild damage at the acute phase of the IP bleomycin model. 
Evans blue dye extravasations revealed that although vascular permeability was 
enhanced following bleomycin exposure, there was no further loss of vascular 
barrier function in mice lacking the A2BR (Figure 4.4, A and B).  
These findings suggest that IT bleomycin exposure results in an acute 
damage, making vasculature the fundamental barrier in preventing neutrophil 
infiltration and injury to the lung. Thus, there is enhanced loss of vascular barrier 
function and pulmonary neutrophilia in A2BR-/- mice at the acute stage of the 
disease. In contrast, IP bleomycin model does not involve an acute damage and 
there is only mild vascular damage in mice exposed to bleomycin and no further 
loss of barrier function in A2BR-/- mice at the acute stage of the disease. 
 
DISCUSSION 
In the previous chapter, we observed that the genetic removal of the A2BR 
results in loss of vascular barrier function in ADA-deficient mice. This may 
e 
s, 
contribute to the enhanced pulmonary injury at the acute stage of disease in 
ADA/A2BR double knockout mice, leading to the precocious death of thes
animals compared to ADA-deficient mice. However, in the same model, A2BR 
antagonism resulted in diminished pulmonary inflammation and fibrosi
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suggesting a tissue-destructive role of this receptor at chronic stage of the 
disease. The discrepancy between these two studies could be due to the fact 
that the A2BR antagonist was given after the disease status has been 
established, while the genetic knockout totally abolished the receptor activity 
from birth of the animals. Therefore, in ADA-deficient model, the A2BR may have 
a bi-phasic effect on disease progression that it plays an important role in 
maintaining vascular barrier function during acute injury and serves a pro-
inflammatory and pro-fibrotic role during the chronic phase of the disease. In 
order 
is in the 
terstitial areas of the lung, an acute inflammation characterized by neutrophil 
olved before the fibrotic changes. The instant damage caused by 
bleomy
to further address this concept, I chose bleomycin-induced pulmonary 
injury as the model to investigate the distinctive roles of the A2BR at different 
stages of the disease. 
The IT bleomycin model involves a single dose of bleomycin exposure 
directly into the lung. The local exposure of the toxic drug results in a severe 
apoptosis of epithelial cells and damage to the lung after it is delivered. In 
addition to the result that mice develop extensive pulmonary fibros
in
infiltration is inv
cin makes vasculature maintanance fundamentally important in 
preventing the infiltration of inflammatory cells. When A2BR-/- mice were exposed 
to bleomycin intratracheally, loss of vascular barrier function at the early stage of 
the disease (Day 7) contributed significantly to the enhancement of pulmonary 
inflammation. Furthermore, this enhanced inflammation counteracted the pro-
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fibrotic role of the A2BR and there was no difference in appearance of the lungs of 
wild type and A2BR-/- mice after the development of fibrosis.  
The generation of adenosine and subsequent A2BR signaling play tissue-
protective roles during acute lung injuries (90). Previous studies have supported 
the protective roles of adenosine and A2BR signaling. For example,  the levels of 
CD39 and CD73, the enzymes to generate adenosine, are elevated in the lungs 
following LPS exposure (37). Moreover, the accumulation of neutrophils following 
LPS stimulation is enhanced in mice deficient in CD39 or CD73. Similar findings 
have been demonstrated in mouse models of hypoxia-induced and ventilator-
induced lung injuries. The levels of CD39 and CD73, and the expression of the 
A2BR are increased during ventilator-induced and hypoxia-induced lung injuries 
(3, 91)
even in a mouse model of chronic lung disease. Studies described in the 
. In addition, the A2BR’s protective roles were revealed by pharmacological 
and genetic approaches. Enhanced pulmonary inflammation, edema, and 
attenuated gas exchange were seen in mice treatment with an A2BR antagonist 
and mice with the A2BR gene deletion  (14, 92). In contrast, treatment with an 
A2BR agonist attenuated the injuries and protected the lungs from drying out (39). 
The A2BR’s protective role was also demonstrated in other organs. A2BR 
blockage or gene deletion resulted in increased weight loss, colonic shortening, 
and disease activity indices in a mouse colitis model, implicating a protective role 
of the A2BR on intestinal epithelial cells (93). Furthermore, the A2BR provides 
potent protection in an intestinal ischemia/reperfusion injury model (94). 
Interestingly, the A2BR plays a protective role at the acute phase of the lung injury 
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previous chapter showed that ADA/A2BR double knockout mice exhibited 
enhanced pulmonary damage and inflammation compared to ADA-deficient mice 
(60). The predominant interface between acute damage and the organs is the 
vascular endothelium. Neutrophil penetrate the endothelium following acute 
damage and vascular endothelial cells create a potential endothelial barrier to 
prevent neutrophil infiltration, loss of fluid and edema formation. All studies 
described above revealed a critical role of the A2BR in attenuating vascular 
leakage through endothelial paracellular barriers. Hence, loss of vascular barrier 
function due to A2BR deficiency is responsible for the enhanced pulmonary 
inflammation and damage in A2BR-/- mice following acute lung injuries.  
The mechanism by which the A2BR prevents vascular leakage is unknown. 
However, it has been proposed that signaling pathways through cAMP, 
subsequent phosphorylation of VE-cadherin and vasodilator-stimulated 
phosphoprotein, and alterations in cellular cytoskeleton are responsible for the 
enhanced vascular barrier function (3, 68, 95, 96). In addition, a recent study 
revealed that the neuronal guidance molecule netrin-1 can engage the A2BR on 
neutrophils, providing an unexpected mechanism by which the A2BR may play a 
protective role (97). More studies are needed to further investigate how the A2BR 
plays a protective role in maintaining vascular integrity. 
In contrast to the IT bleomycin model where bleomycin was exposed 
directly to the lung, the IP bleomycin model involved 8 doses of bleomycin 
treatments into the peritoneal cavity. Only mild acute injury occurred in this model 
and we did not observe extensive pulmonary neutrophillia throughout the 
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protocol. An acute phase inflammatory response was not as robust in this model 
as that in the IT bleomycin model. In addition, although there was still vascular 
damage and increased vascular permeability after bleomycin treatments at the 
early stage, vascular barrier function was not a determinant factor in preventing 
inflammation and damage in the lung. Mice did develop fibrosis in the lung and 
pulmonary fibrosis was assessed on Day 33. A2BR-/- mice showed diminished 
pulmonary fibrosis compared to wild type mice, suggesting the A2BR is playing a 
pro-fibrotic role. This finding suggests that the A2BR only helps in maintaining 
vascular integrity when an acute damage is involved; it plays a pro-fibrotic role at 
the chronic stage of the diseases. 
The observation in the IP bleomycin model is consistent with the findings 
in A2BR antagonism study in ADA-deficient mice, where a pro-fibrotic and tissue-
destructive role of the A2BR was revealed (57). Numerous studies support the 
A2BR’s detrimental roles. The activation of the A2BR promotes fibroblasts 
differentiation into myofibroblasts and hence promotes collagen production and 
deposition (30). The engagement of the A2BR on human mast cells mediates the 
expression of various pro-inflammatory cytokines such as IL-4, IL-8 and IL-13 
(52, 55, 56, 98, 99). A2BR activation up-regulates the production of IL-6 from 
mouse macrophages (75). These findings implicate a detrimental effect of the 
A2BR in promoting the damage and injury at the chronic stage of the disease. 
In conclusion, the results of the present study demonstrate that A2BR plays 
a protective role in maintaining the integrity of vascular barrier when an acute 
injury is involved. On the other hand, the activation of A2BR promotes the 
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production of pro-fibrotic cytokines and chemokines and it plays a pro-fibrotic and 
tissue-destructive role at the chronic stage of the disease. As a result, adenosine 
and the A2BR regulate both the protective and detrimental aspects in diseases. 
A2BR antagonist could be beneficial in treating chronic lung disease, especially at 
the later stages; A2BR agonist could be useful in treating patients with acute 
respiratory distress and protecting the vascular barrier. Further studies are 
needed to understand the status of adenosine metabolism and A2BR signaling in 
specific patients of these diseases in order to design adenosine-based therapies 
to treat these patients. This will be the focus of the next chapter.  
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CHAPTER 5 
ALTERATIONS OF ADENOSINE METABOLISM 
AND SIGNALING IN PATIENTS WITH CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE AND 
IDOPATHIC PULMONARY FIBROSIS 
 
Findings in the previous chapters suggest that the A2BR plays a protective 
le in acute lung injury but a destructive role in chronic lung diseases. It is 
critical to better understand adenosine metabolism and signaling in each specific 
disease in order to design potential adenosine-based therapeutics. Studies 
described in this chapter focus on in stigating adenosine metabolism and 
signaling, specifically A2BR signaling, in two types of human chronic lung 
diseases.  
    
INTRODUCTION 
Adenosine and Human Chronic Lung Disease 
The production of adenosine in the lungs of asthmatics and COPD 
tients suggests that it may regulate aspects of lung disease (1, 100). There is 
substantial clinical and scientific evidence to support this hypothesis. Adenosine 
n directly influence cellular and physiological processes in the lungs of 
thmatics and patients with COPD (24, 100). For example, exogenous 
ro
ve
pa
ca
as
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adenosine can elicit acute bro atients with asthma or COPD 
(101, 102), while no effect was found on normal individuals, suggesting a 
fun or 
bin e 
significantly decreased affinity of the A R, A R, and A R in patients with COPD 
comp sity 
of A2BR wa rol group, 
but the affinity was not altered (103).  The signaling pathways of adenosine can 
influence the activity of multiple cell types that play a critical role in chronic lung 
disease including, mast cells (104), eosinophils (35), macrophages (105), 
epithelial cells (36), fibroblasts (30), and smooth muscle cells (106). Recent 
studies directly implicate adenosine in the regulation of pulmonary fibrosis. 
Exposure of human pulmonary fibroblasts to adenosine promotes differentiation 
into myofibroblasts through mechanism that involved the A2BR (30). Moreover, 
A2BR engagement promotes the production of fibronectin from type II epithelial 
cells (107), a process that can impact pulmonary fibrosis. Lastly, it has been 
shown that the expression levels of A2BR are elevated in remodeled airway 
epithelial cells when comparing rapidly progressing idiopathic pulmonary fibrosis 
patients to slowly progressing patients (108). Collectively, these studies 
demonstrate that adenosine can regulate processes that influence pulmonary 
fibrosis.  
 
 
nchoconstriction in p
damental difference regarding adenosine signaling in these patients. Recept
ding studies to analyze adenosine receptor expression revealed th
1 2A 3
ared with controls, whereas increases in density was observed. The den
s decreased in patients with COPD compared with the cont
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Purinergic Remodeling in Animals Models of Chronic Lung Disease 
Examination of adenosine levels in animal models of chronic lung disease 
support these findings in humans. Transgenic mice that over express the TH2 
cytokines IL-4 or IL-13 in the lungs develop progressive pulmonary inflammation 
and injury characterized by eosinophilic and monocytic infiltrates, airway fibrosis 
and alveolar airspace destruction in association with increases of adenosine 
levels in the lungs (66, 109). In addition, adenosine levels are elevated in the 
lungs of mice exposed to the fibrosis inducing agent bleomycin (110) or following 
chronic ovalbumin exposure (111). Lastly, there are correlations between the 
degree of inflammation and damage and adenosine accumulations in ADA-
deficient mice (47). Therapeutic strategies to lower adenosine levels or disrupt 
adenosine receptors lead to improvement in pulmonary pathologies in these 
models. We have made the observation that the levels of key components of 
adenosine metabolism and signaling are altered in these mouse models where 
adenosine-based therapeutics are most effective. These changes include a 
selective down-regulation of ADA, the major enzyme for adenosine metabolism, 
the up-regulation of ecto-5’-nucleotidase (CD73), the major enzyme of adenosine 
production, the down-regulation of adenosinie kinase (AK) and equilibrative 
nucleoside transporters (ENT) (Figure 1). In addition, we have observed up-
regulation of pro-inflammatory and pro-fibrotic adenosine receptors in these 
models (47, 66, 109, 110). This is a process we call purinergic remodeling. 
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Experimental Rational and Goals 
These
ing in 
uman chronic lung diseases, and provides insight into potential mechanisms for 
creening patients for trials in adenosine-based therapies.  
 findings raise the possibility that adenosine-based therapeutics may be 
beneficial in the treatment of chronic lung disease such as COPD and IPF. If 
changes in purinergic metabolism and signaling also exist in humans with COPD 
and IPF, it would provide proof of concept information that these disorders may 
benefit from adenosine-based therapeutics. The focus of the study described in 
this chapter was to utilize tissues and from the Lung Tissue Research 
Consortium (LTRC) to determine if “purinergic remodeling” exsits in patients with 
COPD and/or IPF. Patients were classified as Stage 0 COPD, Stage 4 COPD, 
Mild IPF and severe IPF according to spirometry, pathological specimen and high 
resolution CT scan (Figure 5.1). Our hypothesis was that purinergic metabolism 
and signaling components are altered in a manner that promotes adenosine 
production in tissue samples from patients with COPD and IPF. Our results 
demonstrate that CD73 and the A2BR are elevated in lung biopsy samples from 
patients with Stage 4 COPD and Severe IPF compared to patients with 
preserved lung function. This was associated with significant alterations in 
expressions of pro-inflammatory mediators known to be driven by A2BR signaling 
in animal models, and ex vivo studies demonstrated that activation of the A2BR 
can influence the production of key inflammatory and fibrotic mediators from 
macrophages isolated from these patients. This study provides novel and 
important information into the potential involvement of adenosine signal
h
s
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Transcript Levels of Components of Adenosine Metabolism and Signaling 
 and 2.5 fold, 
Are Altered in the Lungs of COPD and IPF Patients 
Components of adenosine metabolism and signaling are altered in mouse 
models of chronic lung disease in association with elevated levels of adenosine 
(47, 66, 109, 110). Total RNA was isolated from lung biopsy specimens and real-
time RT-PCR was performed to quantify key components of adenosine 
metabolism and signaling. Results demonstrated a 3 fold increase of CD73 
transcripts in whole lung RNA extracts from Severe IPF and Stage 4 COPD 
patients compared to Mild IPF and Stage 0 COPD patients with preserved lung 
function (Figure 5.2A). However, the transcript levels of ADA, AK and ENT1 were 
not altered in Severe IPF and Stage 4 COPD patients (Figure 5.2, B-D). All four 
adenosine receptors were detectable in subjects with preserved lung function 
(Figure 5.2E). Transcript levels for the A2BR were significantly increased in 
Severe IPF and Stage 4 COPD patients (Figure 5.2E). These findings 
demonstrate elevations in components of adenosine production and A2BR 
signaling in the lungs of patients with progressive chronic lung disease. 
 
CD73 and ADA enzymatic activities are altered in the lungs of COPD and 
IPF patients 
To examine alterations in enzymatic activities of the key enzymes of 
adenosine metabolism, protein extracts were made from lung biopsy specimens 
and enzymatic activities of CD73 and ADA were quantified using HPLC (Figure 
5.3). The enzymatic activity of CD73 was increased by 2 fold
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 Figure 5.1 
Lung histopathology and high-resolution CT scans.  Representative H&E stainin
and hign-resolution CT scan images showing:  (A) A Stage 0 COPD pa
preserved lung function.  (B) A Mild IPF patient with preserved lung functio
g 
tient with 
n.  (C) A 
Stage 4 COPD patient.  (D) A Severe IPF patient.  Sections are representative of 
10-14 different patients from each group. 
  
 
RESULTS 
Figure 5.2 
Expression of components of adenosine metabolism and signaling.  Transcript 
arious enzymes in adenosine metabolism, and adenosine receptors levels of v
were quantified in lung RNA extracts from patients using quantitative RT-PCR.  
Shown are levels of (A) CD73, (B) ADA, (C) AK, (D) ENT1, (E) Adenosine 
receptors.  Results are presented as mean percentage of 18sRNA transcripts ± 
SEM. *p ≤ 0.05 versus Mild IPF. # p ≤ 0.05 versus Stage 0 COPD. n = 4 (Stage 0 
COPD), n = 10 (Mild IPF), n = 8 (Severe IPF and Stage 4 COPD).  
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Figure 5.3 
Determination of enzyme activity and representative chromatograms. (A) CD73 
enzyme activity. Adenosine was quantitated by reverse phase HPLC, measuring 
a t 260nm. Chromatogram in the upper panel represents a typical curve 
n 
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t 
. 
. 
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A 
B 
bsorbance a
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at
om a nucleotidase assay. The AMP peak is seen at 8 min, with adenosine detectio
 around 13 min. Samples that have been preincubated with the enzyme inhibitor o
at inactivated were used as controls (middle and lower panel). (B) ADA enzyme
tivity. Inosine was quantitated by reverse phase HPLC, measuring absorbance a
0nm. Chromatogram in the up panel represents a typical curve from an ADA assay
he Adenosine peak is seen at 13 min, with inosine detection at around 10 min
amples that have been heat inactivated were used as controls (lower panel).  
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Figure 5.4 
CD73 and ADA enzymatic activity.  CD73 (A) and ADA (B) enzyme activity were 
quantified in lung protein extracts from patients.  Reaction mixtures were 
separated, identified, and quantified by HPLC.  Data are presented as mean 
nanomoles of substrate converted to product per min per milligram of protein ± 
SEM. *p ≤ 0.05 versus Mild IPF. # p ≤ 0.05 versus Stage 0 COPD. n = 4 (Stage 0 
COPD), n = 10 (Mild IPF), n = 8 (Severe IPF and Stage 4 COPD). 
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respectively, in Stage 4 COPD and Severe IPF patients compared to subjects 
with preserved lung function (Figure 5.4A). This finding is consistent with 
increased CD73 RNA levels and suggests that its expression is altered to 
promote adenosine generation in patients with severe chronic lung disease. 
There was a significant decrease in ADA enzymatic activity in Severe IPF 
patients and Stage 4 COPD patients compared to subjects with preserved lung 
function (Figure 5.4B). These observations also suggest that purinergic 
remodeling exist in these patients and it promotes adenosine elevations.  
 
Cellular localization of CD73 and A2BR expression in lung tissue from 
COPD and IPF patients 
o identify the cellular localization of key components of adenosine 
and signaling in normal and diseased subjects, tissue sections were 
CD73 was expressed on inflammatory cells and endothelial cells (Figure 5.5C, 
arrow). In Severe IPF patients, CD73 was localized to inflammatory cells, 
endothelial cells and remodeled airway epithelial cells (Figure 5.5D, arrow). 
A2BRs were localized on inflammatory cells, mostly macrophages in both Stage 0 
and Stage 4 COPD patients (Figure 5.6, A and C). In IPF patients, A2BRs were 
xpressed on inflammatory cells and stromal cells (Figure 5.6, B and D) as well 
s hyperplastic cells in remodeled airways (Figure 5.6F).  
T
metabolism 
stained with antibodies against CD73 and A2BR. In Mild IPF and Stage 0 COPD 
subjects with normal lung function, CD73 was expressed on inflammatory cells 
as well as endothelial cells (Figure 5.5, A and B). In Stage 4 COPD patients, 
e
a
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Figure 5.5 
sections were stained with antibodies against CD73.  
(A) Lung section from a Stage 0 COPD patient.  (B) Lung section from a Mild IPF 
C) Lung section from a Stage 4 COPD patient.  (D) Lung section from a 
Severe IPF patient.  Sections are representative of 10-14 different patients from 
μm.  ( ) CD73 positive inflammatory cells were 
quantified in 20 images.  Data are presented as mean number of positive cells 
≤ 0.05 versus Stage 0 COPD. #p ≤ 0.05 versus Mild IPF. 
n = 4 (Stage 0 COPD and Mild IPF), n = 8 (Stage 4 COPD 
Localization of CD73.  Lung 
patient.  (
each group.  Scale bars=100 E
per 10X field ± SEM. *p 
and Severe IPF).  
 
  
 
 
 
Figure 5.6 
Localization of the A2BR.  Lung sections were stained with antibodies against the 
A2BR.  (A) Lung section from a Stage 0 COPD patient.  (B) Lung section from a 
Mild IPF patient.  (C) Lung section from a Stage 4 COPD patient.  (D) Lung 
section from a Severe IPF patient.  Sections are representative of 10-14 different 
patients from each group. Scale bars=100 μm.  (E) A2BR positive inflammatory 
cells were quantified in 20 images. (F) Lung section from an IPF patient. Data are
presented as mean number of positive cells per 10X field ± SEM. *p ≤ 0.05 ve
 
rsus 
tage 0 COPD. #p ≤ 0.05 versus Mild IPF. n = 4 (Stage 0 COPD and Mild IPF), n 
= 8 
S
(Stage 4 COPD and Severe IPF).
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xpression of CD73 and the A2BR in M2 macrophages.  Lung sections from COPD 
r IPF patients were reacted with antibodies against CD73 (A, green) or the A2BR 
, green) together with the M2 macrophage marker CD206 (red).  In the merged 
ages, yellow represents co-localization of CD73 or the A2BR and the M2 marker, 
lue is dapi stained nuclei.  Sections are representative of 10-14 different patients 
rom each group. Scale bars=100 μm. 
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Alternatively activated macrophages, known as M2 macrophages, are 
involved in microenvironments with prolonged inflammation and fibrosis (112, 
113). To determine if M2 macrophages express CD73 and the A2BR, co-
localization studies using an M2 macrophage marker, CD206 and CD73 or A2BR 
antibodies were conducted on sections from these patients. Results 
demonstrated that M2 macrophages express high levels of CD73 (Figure 5.7A) 
and A2BR (Figure 5.7B) in Stage 4 COPD and Severe IPF patients. 
 
Transcript levels of pro-inflammatory mediators downstream of adenosine 
signaling are altered in the lungs of COPD and IPF patients 
Adenosine A2BR signaling has been shown to regulate the expression of 
certain inflammatory and fibrotic mediators in cell types and lung tissue 
associated with chronic lung disease (53, 56-58, 70, 75). Total RNA was isolated 
from lung biopsy specimens and real time RT-PCR was performed to quantify 
key mediators that have been shown to be regulated by A2BR signaling. Results 
demonstrate that transcript levels of IL-6, IL-8 and osteopontin are all increased 
in both Stage 4 COPD and Severe IPF patients compared to subjects with 
normal lung function (Figure 5.8, A-C). These findings suggest that the 
expression of these pro-inflammatory and pro-fibrotic mediators that might be 
regulated by A2BR signaling is elevated in these patients.  
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Figure 5.8   
Expression of pro-inflammatory mediators.  Transcript levels of various cytokines 
and chemokines were quantified in lung RNA extracts from patients using 
quantitative RT-PCR.  Shown are levels of (A) IL-6, (B) IL-8, (C) OPN.  Results 
re presented as mean percentage of 18sRNA transcripts ± SEM. *p ≤ 0.05 
versus Mild IPF. # p ≤ 0.05 versus Stage 0 COPD. n = 4 (Stage 0 COPD), n = 10 
(Mild IPF), n = 8 (Severe IPF and Stage 4 COPD). 
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Figure 5.9 
Associations between the expression of CD73, A2BR and inflammatory mediators.  
The transcript levels of CD73 in individual COPD and IPF patients were 
associated with transcript levels of the A2BR (A).  In IPF patients, the 
 
significantly 
transcript levels of IL-6 (B) and IL-8 (C) were significantly correlated with the
transcript levels of CD73; the transcript levels of IL-8 (D) and OPN (E) were 
significantly correlated with the transcript levels of A2BR. 
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Correlations between the transcript levels of A2BR, CD73, and 
inflammatory/fibrotic mediators 
To investigate the associations between CD73, the A2BR and mediators, 
correlations were determined using linear regression. Among all the subjects 
analyzed, the transcript levels of CD73 significantly correlated with the transcript 
levels of A2BR (Figure 5.9A). Although significant correlations were not found in 
COPD patients, in IPF patients, the transcript levels of IL-6 and IL-8 significantly 
correlated with the transcript levels of CD73 (Figure 5.9, B and C); and the 
transcript levels of IL-8 and OPN significantly correlate with the transcript level of 
A2BR (Figure 5.9, D and E).  
 
A2BR Signaling in M2 macrophages contributes to the production of IL-8 
and IL-6 
To determine if the A2BR on M2 macrophages is directly involved in the 
induction of pro-inflammatory/fibrotic mediators, human primary alveolar 
macrophages were isolated from the BAL fluid of Severe IPF and Stage 4 COPD 
patients. Co-localization studies using an M2 macrophage marker, CD206 and 
2BR antibodies were conducted on cells of an IPF patient. 
NECA exposure. This resulted in a loss of NECA-stimulated increases in IL-8 
and IL-6 protein levels in the media (Figure 5.10B). Interestingly, A2BR inhibition  
either CD73 or A
Results demonstrated that the macrophages were M2 macrophages, which 
expressed both CD73 and the A2BR (Figure 5.10A). Primary alveolar 
macrophages were then pretreated with an A2BR antagonist (CVT-6883) before 
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Figure 5.10  
A2BR-dependent IL-8 and IL-6 expression in human primary alveolar macrophages. (
Cells from an IPF patient were reacted with antibodies against CD73 (A, upper 
green) or the A2BR (A, lower panel, green) together with the M2 macrophage marker 
CD206 (red).  In the merged images, yellow represents co-localization of CD73 o
A2BR and the M2 marker, blue is dapi stained nuclei. (B) ELISA measurements of IL-8 
and IL-6 production from macrophage cultures of IPF and COPD patients. Res
A) 
panel, 
r the 
ults are 
presented as mean concentrations of cytokines ± SEM. *p ≤ 0.05 versus cells without 
any treatment. #p ≤ 0.05 versus cells treated with NECA alone. n = 6.  
  Figure 5.11  
A2BR-dependent IL-8 and IL-6 mRNA expression in human primary alveolar 
es from IPF patients. Real-time PCR measurements of IL-8 (A) and IL-6 macrophag
(B) mRNA expression from macrophage cultures of IPF patients. Results are 
presented as mean percentage of 18sRNA transcripts ± SEM.. *p ≤ 0.05 versus 
cells without any treatment. #p ≤ 0.05 versus cells treated with NECA alone. n = 6.  
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can decrease the base line production of IL-8 and IL-6 in cell cultures from the 
IPF patient, suggesting these cells are already activated and adenosine 
produced from these cells can activate the A2BR and contribute to IL-8 and IL-6 
production (Figure 5.10B). Consistent to the levels of protein release into the 
macrophage culture media from IPF patients, IL-8 and IL-6 mRNA levels are 
altered in a similar pattern in response to NECA and/or CVT-6883 (Figure 5.11), 
suggesting that A2BR signaling directly regulates gene transcription rather than 
protein release. These findings demonstrate that IL-8 and IL-6 expression is 
regulated by engagement of the A2BR on alveolar macrophages isolated from the 
lungs of IPF and COPD patients. 
 
DISCUSSION 
Adenosine is a nucleoside and signaling molecule that is generated in 
response to cell stress or damage. Substantial evidence indicates that there are 
elevated adenosine levels in patients with chronic lung disease. Elevation of 
adenosine levels were seen in BAL fluid collected from asthmatics (25), in the 
exhaled breath condensate of patients with allergic asthma (114), in plasma in 
sthmatic subjects following bronchial provocation with allergen (115), and 
a ercise-induced asthma (116). In addition, elevated adenosine 
v
1
o se models exhibiting features of chronic lung disease (66, 109, 110), 
uggesting adenosine is sufficient to access pathways that lead to the 
a
p tients with ex
le els have been found in sputum samples from patients with cystic fibrosis 
7). Consistent with that, elevated adenosine levels are found in various (1
m u
s
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development of the features of chronic lung disease. In addition, the levels of key 
components of adenosine metabolism and signaling are altered in these mouse 
models to promote adenosine accumulation and tissue-destructive adenosine 
receptor signaling, a process known as purinergic remodeling. Our hypothesis 
was that purinergic remodeling also exists in patients with COPD and/or IPF. 
This would provide direct evidence that chronic lung diseases such as COPD 
and IPF may benefit from treatment with adenosine-based therapeutics. 
CD73 is the major extracellular enzyme for adenosine production. CD73 
levels were found to be up-regulated in the lungs of ADA-deficient mice and mice 
exposed to bleomycin (47, 110). In addition, bronchial cultures from patients with 
ystic fibrosis exhibited 3-fold higher CD73 activity than normal cultures (118). 
suggest that the up-regulation of CD73 is an important purinergic 
remod
c
These findings 
eling response in lung where adenosine-dependent injury is present. In the 
current study, we observed that the transcript levels of CD73 are elevated in both 
Severe IPF and Stage 0 COPD patients compared with subjects with normal lung 
functions. Consistent with this, the enzymatic activity of CD73 is significantly 
increased in Severe IPF and Stage 4 COPD patients, suggesting there is an 
increased capacity for adenosine production in these patients compared to 
normal subjects. To localize CD73 in the lung, immunostaining showed CD73 is 
expressed on endothelial cells, inflammatory cells in normal lungs and 
endothelial cells, inflammatory cells and remodeled airway epithelial cells in 
diseased lungs. This demonstrates that at the sites of inflammation and tissue 
remodeling, there is excessive amounts of adenosine generated.  
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ADA is the major adenosine metabolic enzyme that deaminates 
adenosine to inosine both intracellularly and extracellularly. Mice over expressing 
the TH2 cytokine IL-4 or IL-13 in their lungs showed down-regulated ADA 
transcripts and enzymatic activity along with elevated lung adenosine levels and 
severe pulmonary inflammation, fibrosis and alveolar destruction (66, 109). 
Similar findings were observed in the lungs of mice treated with bleomycin (110). 
Our findings suggest that although the transcript levels of ADA are not changed 
in IPF
nly adenosine 
 and COPD patients, the enzymatic activity of ADA is significantly reduced 
in Stage 4 COPD and Severe IPF patients compared to subjects with normal 
lung function. Post-transcriptional regulations of ADA mRNA could contribute the 
discrepancy between the transcript and protein levels of ADA. Nonetheless, there 
seems to be less adenosine consumption, which could also contribute to higher 
levels of adenosine compared to normal subjects.  
Adenosine regulates numerous cellular activities by engaging cell surface 
adenosine receptors. Work from our lab and others have provided evidence that 
adenosine receptor expression is altered in models of lung disease. The A1R, 
A2BR, A3R have been shown to be elevated in the lungs of models exhibiting 
pulmonary fibrosis and alveolar destruction (48, 66, 109, 119). The A2AR, which 
is down-regulated in these models, is thought to be largely an anti-inflammatory 
receptor. The differential expression of these receptors in these models of lung 
disease provides insight into the potential role of adenosine signaling in COPD 
and pulmonary fibrosis. In the current study, although all four adenosine 
receptors are detectable, the transcript level of the A2BR is the o
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recept
 of the A2BR promotes their 
differe
or that is elevated in both Stage 4 COPD and Severe IPF patients 
compared to subjects with normal function. This receptor is mostly localized on 
inflammatory cells as well as lung stromal cells such as airway epithelial cells 
and fibroblasts.  
The A2BR has the lowest affinity for adenosine and is therefore likely 
activated under pathological conditions where adenosine levels are increased. 
A2BR activation has both anti-inflammatory and pro-inflammatory actions and 
both pro- and anti-fibrotic roles (54). Despite the receptor’s homeostatic and 
protective functions during the acute phase of lung injury (14, 58), several studies 
in mouse models have shown that signaling through the A2BR can contribute to 
the pathology and progressive nature of chronic lung diseases such as IPF and 
COPD (30, 57, 70). Substantial evidence has indicated A2BR’s pro-fibrotic 
functions. Studies have shown that engagement
ntiation of pulmonary fibroblasts into myofibroblasts and hence increases 
the deposition of collagen and fibrosis (30). Engagement of the A2BR can 
mediate the direct expression of pro-inflammatory cytokines such as IL-4, IL-8 
and IL-13 from human HMC-1 cells (53, 55), IL-13 from mouse mast cells (56), 
IL-6 and osteopontin from mouse macrophages (48, 57, 75). Consistent with 
these findings, the transcript of levels of IL-6, IL-8 and osteopontin downstream 
of A2BR signaling are elevated in both Severe IPF and Stage 4 COPD patients 
compared to subjects with normal lung function. In IPF patients, the elevation of 
these mediators is in close association with increases in A2BR and CD73. In 
addition, we showed that treatment with a selective A2BR antagonist can prevent 
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the release of IL-6 and IL-8 from macrophages isolated from Severe IPF or Stage 
4 COPD patients. These findings suggest that indeed there is enhanced A2BR 
signaling in these patients and the A2BR antagonist can be useful in treating 
patients with IPF and COPD. 
Substantial evidence in mouse models of chronic lung disease suggests 
that adenosine-based therapeutics may be beneficial for the treatment of chronic 
lung disease where alveolar destruction and fibrosis are prominent. ADA 
replacement therapy consists of intra-peritoneal or intranasal treatment with ADA 
conjugated to polyethylene glycol. This therapy is able to prevent elevations in 
adenosine, or lower the levels of elevated adenosine in various models of lung 
disease (45, 48, 66, 109). Preventing elevations in adenosine using this therapy 
in ADA-deficient mice, IL-13 transgenic mice or IL-4 transgenic mice can prevent 
and reverse TGF-β1 production and fibrosis in the lungs. In addition, lowering 
adenosine levels in the lungs of mice treated with bleomycin leads to reduced 
fibrosis in this model (unpublished data). Thus, adenosine elevations play a 
direct role in accessing pathways that lead to alveolar airway destruction and 
pulmonary fibrosis. The ADA-deficient model of adenosine-dependent pulmonary 
disease has provided a useful mechanism for examining the contribution of 
individual adenosine receptors to the inflammation and damage seen in the lung 
in response to adenosine elevations. A recent study used a selective A2BR 
antagonist (CVT-6883) to block the engagement of this receptor in ADA-deficient 
mice. Treating ADA-deficient mice with this antagonist prevented the production 
of numerous proteases and TGF-β1 from alveolar macrophages, thus preventing 
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the development of alveolar airspace enlargement and pulmonary fibrosis (57). 
Treatment with CVT-6883 also prevented pulmonary fibrosis in the bleomycin 
induced fibrosis model (57). These finding demonstrate that elevations in 
adenosine in the lung can promote airway enlargement and fibrosis in part by 
engaging the A2BR. These findings in mouse models raised the possibility that 
ADA replacement therapy and A2BR antagonist treatment may benefit patients 
with COPD and pulmonary fibrosis. 
A2BR signaling can have distinctive roles in different diseases. It serves a 
tissue-protective role in acute lung injuries, whereas it plays a detrimental role in 
chronic lung diseases. It would be helpful to understand adenosine metabolism 
and signaling in each specific type of disease. Our findings in this chapter 
suggest that adenosine metabolism and signaling components are altered in a 
manner that promotes adenosine production in patients with COPD and IPF. 
These changes include the up-regulation of CD73, a down-regulation of ADA 
activity, and elevated in the A2BR. It provides proof of concept information that 
human COPD and IPF patients may benefit from adenosine-based therapeutics. 
In addition, these changes could help to predict patient populations, where 
adenosine levels are elevated along with up-regulations of CD73, down-
regulations of ADA and enhanced A2BR signaling, may be suitable for therapies 
such as ADA-replacement therapy and A2BR antagonist treatment. 
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CHAPTER 6 
OVERVIEW, FUTURE DIRECTIONS AND 
CONCLUSION 
 
Overview 
Adenosine is a nucleoside signaling molecule produced in response to cell 
stress or damage (120). By signaling through one of the four G-protein coupled 
adenosine receptors, adenosine can influence cellular physiology and 
intracellular signaling pathways through a variety of mechanisms (52, 121, 122). 
One of the most prominent areas of study is the effects of adenosine on immune 
regulation. During acute tissue injury, elevated adenosine levels generally play 
anti-inflammatory and tissue-protective functions. In contrast, sustained 
adenosine elevations in persistent inflammatory conditions, including chronic 
lung diseases such as IPF and COPD, appear to access tissue-destructive and 
pro-inflammatory pathways. The differential activities of adenosine receptors 
have been shown to contribute to the dichotomous role of adenosine. Among the 
four adenosine receptors, the A2BR draws a lot of attention because it has the 
lowest affinity for adenosine. Thus, it can be activated under pathological 
conditions when adenosine levels are elevated and may play important roles in 
disease. Work conducted in this dissertation was designed to better understand 
e role of the A2BR in various acute and chronic aspects of pulmonary disorders. th
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The ADA-deficient mou ates that elevated levels of 
adenosine in the mouse is sufficient to induce lung disease with many of the 
patholog onary 
inflammation, mucus hypers ement, fibrosis and airway 
remodeling.  A previous study in our lab utilized this animal model and showed 
that treatment with a selective A2BR antagonist results in decreased pulmonary 
n, alveolar destruction and pulmonary fibrosis, suggesting the A2BR is 
playing
se model demonstr
ical features seen in human chronic lung diseases, including pulm
ecretion, airspace enlarg
inflammatio
 a tissue-destructive and pro-fibrotic role. In Chapter 3 of this dissertation, 
I took the genetic approach and deleted the A2BR gene from ADA-deficient mice 
to further investigate the role of the A2BR. Surprisingly, ADA/A2BR double 
knockout mice died precociously and exhibited enhanced pulmonary 
inflammation, airspace enlargement, mucus metaplasia and pulmonary fibrosis. 
A major finding in this study was the enhanced vascular permeability in 
ADA/A2BR double knockout mice compared to ADA-deficient mice. We concluded 
that enhanced loss of vascular barrier function in mice lacking the A2BR is 
associated with enhanced pulmonary neutrophilia and enhanced pulmonary 
damage. Although the A2BR has been proven to have tissue-destructive 
functions, it thus appeared to also play an important protective role at early stage 
of the disease in the ADA-deficient model. 
In Chapter 4 of this dissertation, I sought to further address the concept of 
A2BR’s bi-phasic functions. Two bleomycin-induced pulmonary fibrosis models 
were utilized to investigate the A2BR’s distinctive functions at different stages of 
the disease. The IT bleomycin model involves a single bleomycin exposure 
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directly
gested that components of adenosine 
metab
 into the trachea and this local delivery is associated with acute damage 
to the lung. When A2BR-/- mice were exposed to bleomycin IT, enhanced loss of 
endothelial barrier function during the early stages of the pulmonary injury 
resulted in enhanced neutrophil infiltration into the lung and enhanced pulmonary 
damage. This acute inflammation counteracted the pro-fibrotic effect of the A2BR 
so A2BR-/- mice were not protected from bleomycin-induced pulmonary fibrosis. In 
contrast, the IP bleomycin model does not involve extensive acute lung damage 
or inflammation, and in this case, A2BR-/- mice were protected from bleomycin-
induced pulmonary fibrosis. These results demonstrate that the A2BR plays a 
protective role in attenuating vascular leakage at the acute phase of the disease, 
whereas it exhibits pro-inflammatory and pro-fibrotic roles in chronic lung 
diseases. These findings highlight the complexity of A2BR signaling and suggest 
that it would be critical to investigate the status of A2BR in specific diseases.  
In different mouse models of pulmonary fibrosis, molecules involved in 
adenosine metabolism and signaling are altered to promote adenosine 
production (22, 66, 109-111, 123, 124). In Chapter 5 of this dissertation, human 
samples from IPF and COPD patients were utilized to examine the status of 
adenosine metabolism and signaling to determine if these changes exist in 
human chronic lung diseases. Findings sug
olism and signaling are altered in a manner that promotes adenosine 
production in patients with COPD and IPF. These changes included the up-
regulation of CD73, a down-regulation of ADA activity, and elevated A2BR 
expression. In addition, mediators that are regulated by the A2BR, such as IL-6, 
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IL-8 and osteopontin were elevated in these samples and activation of the A2BR 
on macrophages isolated from the airways of COPD and IPF patients was shown 
to directly induce the production of these mediators. This study provides proof of 
concept information that A2BR signaling can promote the production of 
inflammatory and fibrotic mediators in patients with these disorders and these 
disorders may benefit from adenosine-based therapeutics such as exogenous 
ADA enzyme therapy or A2BR antagonist treatment.  
Various studies in cellular and animal models provide substantial evidence 
that adenosine signaling through adenosine receptors can serve both protective 
and detrimental roles (90) (Figure 6.1). Adenosine and A2BR’s tissue-protective 
role partially comes from its role in the maintenance of pulmonary barrier function 
(3, 14, 15). In lung injuries where the damage to the lung is accompanied by 
disruption of endothelial barriers, the A2BR plays an important role in maintaining 
vascular endothelial cell junctions and creating a potential endothelial barrier to 
prevent neutrophil infiltration. Studies described in this dissertation revealed a 
critical protective role of the A2BR in attenuating vascular leakage through 
endothelial paracellular barriers. In addition, A2BR signaling may also promote 
the normal function of CFTR, contribute to the maintenance of airway surface 
liquid height in airway epithelial cells, and prevent mucus stasis in the airways. 
The local cytokine milieu in different diseases may play an important role 
in regulating the anti- or pro-inflammatory actions of adenosine. Acute lung 
injuries are associated with elevations in IL-12, IFNγ and TNFα and a TH1 
dominated environment. Adenosine signaling usually serves to down-regulate the 
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production of TH1 cytokines (125). In contrast, a lot of chronic lung diseases 
such as asthma, COPD, and interstitial lung diseases are associated with 
elevations in TH2 cytokines such as IL-4, IL-5, IL-8 and IL-13 (2). Adenosine 
acting through the low affinity A2BR can increase the production of TH2 cytokines 
from various cell types (53, 55, 56, 99) (Figure 6.1). In mast cells, A2BR activation 
can stimulate the production of the TH2 cytokines that regulate both airway 
constriction and inflammation. In addition, the A2BR can promote the production 
of me
y 
pharm
diators from macrophages. Previous studies have shown that A2BR 
activation stimulates the production of IL-6 and osteopontin from mouse 
macrophages (126). My result was the first evidence to show it can also promote 
the production of IL-6 and IL-8 from human alveolar macrophages. Furthermore, 
activation of the A2BR on fibroblasts promotes the release of IL-6 and stimulates 
the differentiation into myofibroblasts (30), which play a key role in the production 
of extracellular matrix and fibrotic remodeling. These findings suggest that 
adenosine signaling is detrimental and can contribute to the amplification or 
progression of chronic lung disease 
 Taken together, patients with either acute lung injury or chronic lung 
disease may both benefit from adenosine-based therapeutics. Compounds 
selectively targeting adenosine receptors are under development b
aceutical companies. For example, The selective A2BR antagonist, CVT-
6883 has completed phase I clinical trials with no adverse events reported (127); 
however, efficacy in phase II trials has not yet been shown. Due to the 
complication of adenosine receptor signaling in different aspects and at the 
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different stages of the disease, the development of adenosine-based 
therapeutics can be challenging. It is critical to determine the right adenosine 
receptor as the drug target, whether to activate or inhibit it in any particular type 
of disease. Moreover, the dosage and timing of the drug exposure can also be a 
determinant factor in order to prevent any unwanted side effects. In acute lung 
injuries where a TH1 environment is commonly involved, the A2BR plays a critical 
role in maintaining vascular barrier function; when these patients fail the wound 
healing response and develop chronic lung diseases, A2BR signaling promotes 
the release of pro-inflammatory cytokines and contributes to disease progression 
(Figure 6.2).  
My findings in this dissertation suggest that A2BR agonist could be useful 
in treating patients with acute lung injuries; whereas A2BR antagonist can be 
used to treat chronic lung diseases. Timing of these treatments can be critical. 
A2BR agonist to treat acute lung injuries may only be beneficial at the acute 
phase of the disease; A2BR antagonist to treat chronic lung disease may only be 
effective at the late stage of the disease, whereas treatment early in the disease 
may cause vascular leakage and enhanced injury. In addition, my findings 
provide a novel method to identify the subset of patients with chronic lung 
disease that may benefit from adenosine-based therapeutics. It would be helpful 
to conduct bronchoscopy on patients with IPF or COPD, isolate alveolar 
macrophages and determine if the production of pro-inflammatory cytokines from 
these macrophages respond to A2BR agonist or antagonist. If macrophages  
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Figure 6.1  
promote endothelial barrier 
ASL height in airway epithelia
can als
 
A2BR activities in pulmonary cells. Adenosine signaling through the A2BR can 
function and serve important anti-inflammatory and 
tissue-protective roles. A2BR signaling also contributes to the maintenance of 
l cells. In contrast, the A2BR contributes to the 
production of IL-8, IL-4, IL-13, and VEGF from mast cells. A2BR engagement 
o promote the production of osteopontin, IL-6, and IL-8 from 
macrophages; IL-6 release from fibroblasts and myofibroblasts differentiation.  
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Figure 6.2  
 
 
 
 
 
Model of A2BR signaling in acute and chronic lung disease. In acute injury,
adenosine and the A2BR can serve important anti-inflammatory and protective
roles, such as inhibition of Th1 cytokine production and maintenance of
vascular barrier function. In chronic lung disease, A2BR signaling contributes to
the production of Th2 cytokines and promotes the activity of effecter cells such
as mast cells, macrophages and fibroblasts that can drive disease progression. 
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isolated from the patients express high levels of A2BR and the production of IL-8 
and IL-6 from these cells can be promoted by A2BR agonist treatment and 
inhibited by A2BR antagonist treatment, it is very likely that these patients would 
benefit from exogenous ADA enzyme therapy or A2BR antagonists. Additional 
studies are needed to further investigate the specific mechanisms involved in 
adenosine signaling in various pulmonary disorders. 
 
Future Directions 
Treatment of ADA-Deficient Mice with A2BR Agonists 
We have provided substantial evidence that the A2BR plays a protective 
role during the early stage of pulmonary injury when acute inflammation is 
involved, and a tissue-destructive/pro-fibrotic role during the chronic stage of the 
disease. Another direct way to verify this concept is to treat ADA-deficient mice 
with an A2BR agonist at different stages of the disease. A selective A2BR agonist 
B s
fr
ph
D 2B
treatment, we may observe precocious injury and death of these animals 
compared to animals without the agonist treatment. Similarly, this method could 
be utilized in other models of chronic lung disease such as the bleomycin-
induced pulmonary fibrosis model. These studies would raise the possibility that 
A2BR agonist could be used to treat diseases during acute phases. 
AY60-6583  available from Bayer HealthCare. Treating ADA-deficient mice 
om birth with this compound may postpone the development of pulmonary 
enotypes. However, if ADA-deficient mice are kept on PEG-ADA from birth till 
y 21, and then treated with the A R agonist a week after the last PEG-ADA 
i
a
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 Timing and Dosage of A2BR Antagonist Treatment 
Previous studies have shown that the treatment with the selective A2BR 
antagonist, CVT-6883, resulted in diminished pulmonary inflammation and 
damage in ADA-deficient mice and decreased pulmonary fibrosis in the model of 
IT bleomycin-induced pulmonary fibrosis. These results suggest that the A2BR 
lays a pro-inflammatory and pro-fibrotic role in these models. Notably in 
e treatment of the A2BR antagonist did not start and the 
d been established. In 
additio
ue-protective 
p
previous studies, th
receptors were not blocked until the disease status ha
n, other studies, and the findings in this dissertation, support a tissue-
protective role of the A2BR during the acute stage of the disease. It would be 
helpful to treat these animal models with the A2BR antagonist from birth and 
determine if it could mimic the conditions of A2BR gene deletion. It is possible that 
although treatment of the antagonist later would improve pulmonary phenotypes, 
treatment from birth may accelerate the development of the pulmonary damage 
in these animals.  
A discrepancy between pharmacological inhibition and genetic knockout is 
that the receptor’s activity may not be totally inhibited with antagonist treatment, 
while genetic knockout absolutely abolishes the receptor’s activity. Thus, genetic 
deletion may result in loss of homeostatic roles of the receptor that would not be 
revealed by pharmacological inhibition. It will be important to determine the 
dosage of the antagonist that is sufficient to block the tissue-destructive and pro-
fibrotic role of this receptor, but conserves the homeostatic and tiss
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role. This could be done by treating animal models with different doses of the 
athways of the A2BR, such 
as cAM
pithelial cells from wild type and A2BR-/- mice and it would be 
helpful
antagonist and monitoring the down-stream signaling p
P levels, change of vascular permeability and gene transcription profiles.  
 
A2BR Signaling and Mucociliary Clearance 
Previous studies have shown that the A2BR is an important regulator of 
cystic fibrosis transmembrane conductance regulator (CFTR) functions, and 
lacking this receptor may lead to dehydration of airway surface liquid volume and 
mucus stasis (74). Thus, A2BRs are required for airway surface liquid (ASL) 
volume homeostasis and mucus clearance in the airways. This is consistent with 
our findings that there is enhanced mucus metaplasia in ADA/A2BR double 
knockout mice compared to ADA-deficient mice even though mucin gene 
transcription is decreased. Studies conducted with epithelial cells ex vivo would 
provide us a simplified system to investigate the A2BR signaling pathway in 
airway epithelial cells. A standard protocol could be used to isolate mouse 
primary tracheal e
 to compare airway surface liquid height, mucin gene expression, mucus 
production and secretion. 
Mouse tracheal epithelial cells from wild type and A2BR-/- mice could be 
isolated and grown on transwells coated with rat tail collagen. Cells could then be 
maintained for at least 14 days to allow the differentiation and the formation of 
air-liquid interface. β-tubulin staining will be performed on cells from wild type and 
A2BR-/- mice to  compare the number of ciliated cells that contribute to mucus 
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clearance. Airway surface liquid height will be determined by confocal 
microscopy. 10 ng/ml IL-13 could be used to treat tracheal epithelial cells to 
induce mucus metaplasia. Comparisons of mucus production and secretion 
between cells from wild type and A2BR-/- mice could be done by histological 
PCR analysis of mucin gene 
transcr
l demonstrate that the A2BR is important in maintaining 
airway
analysis (mucus staining), real-time RT-
iption, and mucus contents in apical and basolateral media after the 
treatment. NECA, an A2BR agonist could be used to treat epithelial cells after IL-
13 stimulation to determine the functions of A2BR signaling and mucus secretion.  
I expect that tracheal epithelial cells isolated from A2BR-/- mice will have 
fewer ciliated cells and collapsed airway surface liquid height. Both of these will 
contribute to diminished mucus clearance and enhanced mucus deposition on 
airway epithelium. IL-13 treatment will induce mucus metaplasia in wild type and 
A2BR-/- tracheal epithelial cells. Although the same levels of mucus production are 
found in both genotypes, there may be a significant decrease in mucus secretion 
in the apical media of cells isolated A2BR-/- mice, suggesting a mucus secretion 
defect of airway epithelial cells lacking the A2BR. A2BR activation by NECA will 
enhance mucus secretion only in wild type epithelial cells but not in A2BR-/- cells. 
These expected results wil
 surface liquid height, differentiation of ciliated epithelial cells, and mucus 
secretion. 
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Purinergic Remodeling in Normal Subjects in Comparison to Diseased 
Patients 
A major limitation to the study described in Chapter 5 of this dissertation is 
the lack of normal subjects in comparison to subjects with IPF and COPD. 
Although we concluded that adenosine metabolism and signaling in patients of 
IPF and COPD are altered to promote adenosine production, comparisons were 
done between Severe IPF versus Mild IPF, and Stage 4 COPD versus Stage 0 
COPD. Moreover, our ex vivo experiments showing A2BR activation can directly 
regula
teristics of these cells, including the induction of M2 macrophage 
activation, A2BR expression and production of pro-inflammatory/fibrotic 
mediators. 
 
te IL-6 and IL-8 production were performed with cells isolated from Severe 
IPF or Stage 4 COPD patients. A more definitive approach would be to 
characterize purinergic remodeling using frozen tissue and tissue sections, and 
to isolate alveolar macrophages from normal subjects. I expect that the levels of 
CD73, ADA and A2BR would be altered more dramatically in diseased subjects 
when compared to normal subjects. Levels of other enzymes and molecules in 
adenosine metabolism and signaling that did not change in the previous study 
may also be altered. In the ex vivo experiment, macrophages isolated from 
normal subjects are not activated, thus they do not express high levels of A2BR. 
Baseline levels of IL-6 and IL-8 in media of these cells are lower than that of 
activated macrophages from diseased patients. NECA stimulation may change 
the charac
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Adenosine Production in M2 Macrophages 
An interesting finding in the ex vivo experiment using primary 
macro
potential mechanisms for screening patients for potential adenosine-
ased therapeutics that are currently being planned. The findings in this 
phages is that the macrophages isolated from Severe IPF and Stage 4 
COPD patients are already activated and they release high levels of IL-6 and IL-8 
at base line. The A2BR antagonist treatment can significantly decrease the 
release of these mediators. Moreover, these macrophages express the M2 
macrophage marker CD206 and they also express CD73. These findings 
suggest that CD73 in these cells is enzymatically active and adenosine is 
generated at base line. It would be helpful to verify the activity of CD73 by adding 
the inhibitor of CD73, AoPCP, into the cell culture. I expect that the inhibition of 
CD73 would decrease the release of IL-6 and IL-8 at base line, suggesting that 
adenosine is produced from M2 macrophages and it can engage A2BR to play a 
pro-inflammatory role. 
  
Conclusion 
Extensive analysis of inflammation, alveolar destruction, and fibrosis in 
mouse models suggest that adenosine based therapeutics such as ADA enzyme 
therapy and A2BR antagonism would be beneficial in the treatment of human 
conditions such as COPD and IPF. Understanding the involvement of A2BR 
signaling pathways will provide novel and important information into the potential 
significance of adenosine signaling in human lung disease, as well as provide 
insight into 
b
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dissertation suggest that the A2BR is playing a homeostatic and protective role 
during
onists and antagonists in the treatment of acute and 
chronic lung diseases. 
 the acute stage of lung injury; while it plays a pro-fibrotic and tissue-
destructive function during the chronic stage of the disease. As a result, patients 
with acute lung injuries or chronic lung diseases can both benefit from adenosine 
and A2BR-based therapeutics. However, the A2BR may have a bi-phasic effect on 
inflammation and fibrosis and cautions must be taken when designing A2BR 
agonist to treat patients with acute lung injuries, or A2BR antagonist to treat 
human chronic lung diseases. For example, the A2BR antagonist could be 
beneficial in treating patients with chronic lung diseases only when it is given 
after the disease status is established. Additional studies in models as well as 
clinical trials are needed to investigate the roles of adenosine and adenosine 
receptors in each particular disease, and the efficacy of new generations of 
adenosine receptor ag
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